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Zusammenfassung und wissenschaftlicher Erkenntnisgewinn 
 
Trotz massiven medizinischen Fortschritts und ausgiebigen Untersuchungen in der Krebsforschung 
repräsentieren maligne Tumore immer noch eines der größten globalen Gesundheitsprobleme. Daher liegt das 
Auslösen der Apoptose von Tumorzellen seit Jahren im Fokus der Forschung. Neben den klassischen Ansätzen, 
wie Operationen, Strahlen- und Radiotherapie, sowie Chemotherapie wurden neue Methoden zur Behandlung 
von Krebs entwickelt. Hierzu zählt das Konzept der zielgerichteten Therapie, für das monoklonale Antikörper ein 
prominentes Beispiel darstellen. Eine zusätzliche Komponente dieses Ansatzes stellen Antikörper-Wirkstoff-
Konjugate (ADCs) dar, die dem von Paul Ehrlich geprägten Konzept der „Zauberkugel“ entsprechen. Diese Klasse 
von Verbindungen zielen auf den ortspezifischen Transport und die Abgabe eines Zytostatikums an Zielzellen ab, 
die tumorspezifische Antigene exprimieren. Diese Konstrukte kombinieren die Bindungseigenschaften eines 
Antikörpers mit der Toxizität eines Zytostatikums und wurden in zahlreichen Ansätzen für die Krebstherapie 
eingesetzt. So wurden bis heute sechs ADCs kommerziell vermarktet und über 60 werden aktuell in klinischen 
Studien untersucht. Trotzdem besteht weiterhin ein gewisses Verbesserungspotential dieser potenten 
Verbindungen hinsichtlich ihrer Toxizität, Effizienz und pharmakokinetischen Eigenschaften. 
 
Die erste Untersuchung im Rahmen der hier vorliegenden, kumulativen Dissertation fokussierte sich auf die 
Generierung von ADCs, die ein hohes Wirkstoff-zu-Antikörper Verhältnis (DAR) aufweisen und deren Hydrophilie 
durch Anfügen von Zytotoxinen nicht beeinträchtigt wird. Da lediglich ein geringer Anteil des verabreichten ADCs 
tatsächlich die adressierten Zielzellen erreicht, sind entweder hochwirksame oder eine hohe Anzahl weniger 
potenter Zytotoxine unerlässlich, um die gewünschte Effektivität zu erzielen. In Anbetracht des hydrophoben 
Charakters der am häufigsten eingesetzten Zytotoxine weisen diese Konjugate jedoch häufig eine niedrige 
Hydrophilie auf, welche abhängig von der adressierten Konjugationsstelle, der Anzahl und dem Charakter der 
angewendeten Toxineinheiten ist. Folglich hat die Hydrophobizität der konjugierten Zytostatika einen großen 
Einfluss auf die Stabilität sowie die pharmakokinetischen Eigenschaften und bestimmt somit die Effizienz des 
ADCs. So wurde beispielsweise von Problemen bezüglich Aggregation, Erkennung durch multidrug resistance 
(MDR) Rezeptoren und erhöhter Clearance berichtet.  
In dieser Arbeit sollten diese Probleme durch das Design einer neuen Klasse von Hybrid-ADCs gelöst werden, die 
die Hydrophobizität der im Kontext von ADCs weithin genutzten Zytostatika mindern oder sogar gänzlich 
kompensieren kann und zusätzlich die Möglichkeit eröffnet, eine gewünschte Menge dieser potenten Toxine 
pro Antikörper zur Verfügung zu stellen. Zusätzlich sollte eine zukünftige Beladung mit weniger wirksamen und 
folglich weniger schädlichen Toxinen ermöglicht werden, bei denen die reduzierte Toxizität durch eine erhöhte 
Kopienzahl kompensiert wird. 
Dextran, ein von der FDA zugelassenes Polysaccharid, das aus α-1,6-verknüpften Oligoglukoseeinheiten besteht, 
wurde in dieser Arbeit als modulares, multivalenzgenerierendes Grundgerüst für die ortsspezifische Konjugation 
an Antikörper und für die Beladung mit einer gewünschten Anzahl an Zytostatika verwendet. Für die Konjugation 
dieses Glucans an Proteine wurde berichtet, dass sie die Halbwertszeit, die thermische Stabilität sowie die 
pharmakokinetischen Eigenschaften dieser verbessert und deren Immunogenität verringert. Weiterhin bietet 
sich die Möglichkeit, chemische Modifikationen an unterschiedlichen Stellen dieses Zuckermoleküls, zur 
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Einführung orthogonal adressierbarer Gruppen durchzuführen. So kann sowohl eine gewünschte Anzahl an 
Zytostatika an den Hydroxygruppen der Glukose-Wiederholungseinheiten als auch ein Erkennungsmotiv für die 
enzymatische Konjugation an ein Protein an das orthogonal adressierbare Aldehyd am reduzierenden Ende 
angebracht werden. In dieser Arbeit wurde zudem eine Synthesestrategie entwickelt, die es ermöglicht, Dextran, 
beladen mit einer gewünschten Anzahl orthogonal adressierbarer chemischer Gruppen zur Toxinkonjugation, 
mittels Enzymkatalyse ortsspezifisch an einen Antikörper zu konjugieren und anschließend mit Toxinen 
auszustatten. Diese Hybridverbindung ebnete den Weg zur Generierung neuer, vielversprechender hoch 
hydrophiler ADCs mit hohem Wirkstoff-zu-Antikörper Verhältnis. 
Synthetisch wurde hierfür eine reduktive Aminierung mit einem geschützten Diamin am reduzierenden Ende 
mit einer ortsspezifischen Carboxyethylierung an der C2-Position der Glukose-Wiederholungseinheiten 
verbunden, woraus ein Dextran mit zwei unterschiedlich adressierbaren reaktiven Gruppen resultierte. Dabei 
konnte eine gewünschte Anzahl der Carboxygruppen an den Glukose-Wiederholungseinheiten eingestellt 
werden. Anschließend wurden amintragende Azidlinker unter Bildung von Amidbindungen kovalent an den 
eingebauten Carboxygruppen der Glukose-Wiederholungseinheiten eingeführt, woraus ein Dextranrückgrat mit 
multiplen Azid-Funktionalitäten resultierte. Die Demaskierung des geschützten Amins am reduktiven Ende ergab 
schließlich dual adressierbare Polysaccharidgerüste mit multiplen „click“-baren Gruppen zur Konjugation der 
Zytostatika und einem primären Amin, mittels dessen eine enzymkatalysierte Konjugation an den Antikörper 
realisiert werden konnte. Trastuzumab, welcher genetisch mit einer Transglutaminase-Erkennungssequenz 
versehen wurde, diente hierbei als Modellantikörper. Die Konjugation des azidtragenden Dextrangerüsts an 
Trastuzumab unter Katalyse von mikrobieller Transglutaminase und die darauffolgende Konjugation eines 
potenten, sehr hydrophoben Zytoskelettinhibitors (Monomethylauristatin E (MMAE)), bildete ein neues 
Hybridkonstrukt. So wurde Dextran in dieser Arbeit zum ersten Mal ortsspezifisch an einen Antikörper gekoppelt 
und sukzessive mit einer gewünschten Anzahl an Zytostatika durch spannungskatalysierte Azid‐Alkin‐
Cycloaddition (SPAAC) beladen. Diese neuen, als Dextramabs bezeichneten Hybridkonstrukte erwiesen sich 
nicht nur als gut löslich in wässrigen Puffern, sondern auch als mindestens ebenso hydrophil wie der nicht 
modifizierte Trastuzumab, selbst wenn das Polysaccharid mit elf hydrophoben MMAEs beladen wurde. 
Weiterhin zeigten die generierten Konstrukte unveränderte Bindungseigenschaften und keinen 
Stabilitätsverlust (Trastuzumab: KD = 4.9 nM, Dextramab (DAR 8): KD = 5.9 nM). In Zellviabilitätstests zeigten die 
entwickelten Dextramabs potente, subnanomolare mittlere inhibitorische Konzentration (IC50 = 100 pM) auf 
HER2-positiven SK-BR-3 Brustkrebszellen in vitro, wohingegen keine Toxizität für HER2-negative Kontrollzellen 
gefunden wurde. Dextramabs stellen eine neue Strategie für die Generierung ortsspezifisch konjugierter hoch-
hydrophiler ADCs mit einem hohen DAR dar. Tierstudien werden zeigen, ob diese neue Klasse von ADCs ein 
vielversprechendes Konzept zur Generierung von ADCs mit hoher Wirksamkeit, geringer Immunogenität und 
erhöhter in vivo-Halbwertszeit repräsentiert. 
 
In der zweiten Untersuchung wurde die Modularität von Dextran als Träger für Apoptose-induzierende 
Moleküle, die sowohl intrazelluläre als auch Ziele auf der Zelloberfläche adressieren, untersucht. Im Zuge dessen 
wurde, im Gegensatz zum ersten Ansatz, Dextran als eine Plattform zur Multimerisierung von krebsspezifischen 
Liganden untersucht. Der extrazellulär exprimierte Death Rezeptor 5 (DR5) wurde hierfür als Modellziel gewählt, 
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welcher durch Aggregation beziehungsweise Multimerisierung aktiviert wird und eine Apoptose-induzierende 
Signal-Kaskade auslöst (death-inducing singal cascade, DISC). In dieser Arbeit wurde Dextran als Grundgerüst 
mit mehreren peptidischen Liganden (death receptor 5-targeting peptide, DR5TP) von DR5 bestückt und im 
Hinblick auf seine Apoptose-induzierende Wirkung untersucht. Hierbei sollte, im Gegensatz zu der ersten 
Untersuchung, der Zelltod durch Multimerisierung von Rezeptoren auf der Zelloberfläche induziert werden und 
nicht durch rezeptorvermittelte, endosomatische Aufnahme eines an den Antikörper gebundenen 
Zytostatikums. Hierfür wurde Dextran mit 11 respektive 13.4 DR5TP-Liganden beladen und auf seine Apoptose-
induzierende Wirkung untersucht. Die resultierenden multivalenten Dextrangerüste zeigten mit zweistellig 
nanomolaren EC50-Werten (halbmaximalen effektiven Konzentrationen) auf DR5-positiven COLO205-
Kolonzellen und Jurkat T-Lymphozyten eine potente Apoptose-induzierende Wirkung in vitro. Eine 
anschließende ortsspezifische Konjugation an Glutamin 295 eines aglykosylierten kristallisierbaren Fragments 
(Fragment, crystallizable, Fc) mittels mikrobieller Transglutaminase resultierte in Protein-Polysaccharid-
Konjugaten, die eine selektive DR5-Bindung in durchflusszytometrischer Analyse zeigten und die im Vergleich zu 
den nicht an ein Protein konjugierten DR5TP-Dextranen sogar niedrigere EC50-Werte aufwiesen 
(EC50 = 1.9 - 6.7 nM). Interessanterweise wurde die Bindung dieser Konjugate nicht durch den Antikörper, 
sondern durch das mit Liganden bestückte Dextran hervorgerufen. Dies ermöglicht die zukünftige Verwendung 
einer zweiten Bindungseinheit im Hinblick auf bispezifisches Targeting, beispielsweise durch die Konjugation an 
einen Vollängen Antikörper, wodurch eventuell eine höhere Sicherheit und Effizienz realisiert werden könnte. 
Weiterhin ermöglichten die hergestellten Konjugate, sowohl solitär als auch gebunden an das Fc-Fragment, 
durch die erhöhte Flexibilität des Dextranrückgrats die beschriebene distinkte räumliche Anordnung als 
unumgängliche Voraussetzung für effizientes Induzieren von Apoptose zu kompensieren. Dieser Ansatz 
untermauert die Modularität von Dextran als Träger für unterschiedlichste Beladungen, die verschiedene 
Zielstrukturen zur gezielten Auslösung von Apoptose von Tumorzellen adressieren. Zukünftig könnte dieser 
Ansatz einen Lösungsvorschlag für die berichtete Off-target Toxizität von multivalenten hochaffinen 
proteinischen Bindern, wie TAS266, darstellen, da hierin eine höhere Anzahl an Bindern mit niedriger Affinität 
verwendet wird. Dies könnte zu einer geringeren Retention auf gesunden Zellen mit geringerer DR5 
Expressionsdichte und somit einer höheren Verträglichkeit in vivo führen, die zusätzlich durch Einführung von 
Bispezifität erhöht werden könnte. 
 
Der dritte Teil dieser Arbeit sollte einen detaillierten Überblick über die enzymatische Generierung von ADCs 
mittels Transglutaminase geben. Trotz zahlreicher Publikation von Reviews zur Generierung von ADCs fehlt bis 
heute ein Überblick, der die Anwendung von Transglutaminase für diese Therapeutika detailliert beschreibt. Aus 
diesem Grund gibt der verfasste Review einen Überblick über die an dieser Thematik forschenden 
Arbeitsgruppen und Firmen, als auch eine gründliche Übersicht der eingesetzten Methoden, der adressierten 
Konjugationsstellen oder -motive, Linkern und verwendeten Zytostatika. Dieser Review beschreibt und 
diskutiert zukunftsweisende Syntheserouten und -techniken, die jüngsten Fortschritte sowie verbleibende 
Einschränkungen der mTG-unterstützten Generierung von ADCs. 
Zusätzlich wurde eine weitere Studie durchgeführt, die die Verwendung von Dextran als multivalentes 
Grundgerüst untermauert. Hierfür wurde eine vorläufige Studie zur Validierung von Dextran als Träger für 
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multiple chelatierende Komplexbildner, die Ionen für die Radiobildgebung oder -therapie komplexieren können, 
durchgeführt. Hierfür wurde Dextran mit einer gewünschten Anzahl an 1,4,7,10-Tetraazacyclododecan-1,4,7,10-
tetraessigsäure (DOTA) beladen. In einer photometrischen Analyse von komplexierten Cu2+-Ionen konnte 
gezeigt werden, dass die resultierenden DOTA-Dextrankonjugate 3.2 respektive 5.3 Metallionen pro 
Polysaccharidgerüst tragen. Zurzeit werden die hergestellten DOTA-Dextrankonjugate in Biodistributionsstudien 
in Mäusen untersucht. Diese Konzeptstudien werden zeigen, ob diese neuen Konstrukte für in vivo 
Anwendungen geeignet sind und ob eine Konjugation an derzeit verwendete spezielle Bindungsproteine 
(Affibodies), welche in radioaktiv markierter Form Probleme mit der Hydrophobizität und daher mit Solubilität, 
Aggregation und Präzipitation haben, vorteilhaft ist. Dieser Ansatz bestärkt die Vermutung, dass Dextran ein 
vielversprechendes Gerüst für die mehrwertige Befestigung und Anpassung verschiedener Liganden darstellt. 
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Scientific Novelty and Significance 
 
Despite impressive progress in medical care and extensive investigation in the field of human malignancies, 
cancer still represents a major global health issue, and triggering apoptosis of tumor cells has been in focus of 
cancer research for decades. In addition to classical attempts like surgery, radiotherapy, and chemotherapy, a 
number of novel methodologies have recently fallen in the limelight, with monoclonal antibodies being the most 
prominent actors at the therapeutic scene. With their introduction, the so-called targeted therapy has finally 
become achievable for the treatment of malignant tumors. Having evolved from Paul Ehrlich’s “Magic Bullet” 
concept that described directing a toxic compound exclusively to a disease-causing organism, antibody-drug 
conjugates (ADCs) were developed. This class of compounds is aimed at site-selective delivery of cytotoxic 
agents to target cells expressing a cancer-related antigen. Combining the targeting properties of an antibody 
with the killing properties of a potent cytotoxin, these constructs were applied in countless approaches 
intending to treat tumor patients. To date, six ADCs have been marketed and over 60 ones are currently in 
clinical trials. However, several issues still require improvement, among them toxicity, efficacy and 
pharmacokinetics. 
 
The first investigation in the context of the present cumulative study was focused on the generation of highly 
hydrophilic ADCs characterized by a high drug-to-antibody ratio (DAR). However, since only a limited number of 
the administered ADCs is reported to actually reach their cellular target, either highly potent toxins or a higher 
number of the less-potent ones are prerequisites of these compounds to reach efficacy. Considering the 
hydrophobic character of most commonly applied potent cytotoxins, these conjugates often suffer from poor 
hydrophilicity depending on the addressed conjugation site as well as the number and character of the applied 
toxin units. Further, hydrophobicity of ADCs was reported to raise problems due to aggregation and recognizing 
by multidrug resistance (MDR) transporters, thus the number, site, and hydrophobicity of the conjugated toxin 
strongly influences stability, pharmacokinetic properties and the efficacy of ADCs. In this work we addressed 
these issues simultaneously by designing a novel class of hybrid ADCs combining ability to balance and even 
recompense the hydrophobicity of commonly applied highly hydrophobic cytotoxins with an option for the 
attachment of multiple payloads, which may further enable the application of less potent, thus less harmful for 
the healthy tissues, cytotoxins. To that end, we applied dextran, an FDA-approved polysaccharide, consisting 
mainly of α-1,6-linked oligo-D-glucose units as multivalency-generating modular scaffold for payload 
attachment. This glucan, reported to enhance half-life, to improve thermal stability and pharmacokinetic 
properties, and to reduce immunogenicity of conjugated proteins, opens certain space for chemical 
modifications, namely conjugation of a) a desired number of payloads to the repeating glucose units at the 
respective hydroxy groups, and b) at the reducing end that comprises an orthogonally addressable aldehyde. In 
this work, a strategy to combine an enzyme-catalyzed site-specific conjugation of the dextran scaffold, equipped 
with multiple reactive moieties for payload loading, to antibodies was developed, resulting in promising 
constructs for the generation of high-DAR ADCs.  
Synthetically, a combination of reductive amination of dextran’s reducing end with a protected diamine followed 
by site-selective carboxyethylation at the C2-position of the glucose repeating units led to dextran bearing dually 
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addressable reactive moieties. Notably, our synthetic procedure allowed adjustment of the number of 
addressable sites at the repeating glucose monomers for toxin conjugation to the desired amount of copies. 
Subsequent conjugation of azide-bearing aliphatic amines at the repeating units upon amidation gave a scaffold 
comprising multiply addressable “click” sites. Demasking of the protected amine at the reducing end yielded a 
multivalent scaffold combining multiple and solitaire orthogonal addressable sites. Thus, at its amine site it could 
be easily conjugated to the protein of interest – in this particular case, to the therapeutic antibody trastuzumab – 
via enzymatic catalysis by microbial transglutaminase (mTG). For this purpose, trastuzumab was engineered to 
possess an adequate mTG recognition motif at the C-terminus of the heavy chain. The azides at the sugar 
monomers remained for the decoration with monomethyl auristatin E (MMAE) – a highly toxic and extraordinary 
hydrophobic compound. To conclude, for the first-time dextran was site-specifically conjugated to a functional 
antibody via its reducing end, leaving the polysaccharide backbone intact and subsequently equipped with 
multiple MMAEs by strain-promoted azide-alkyne cycloaddition (SPAAC) in a desired number of copies without 
corrupting the polysaccharide backbone. These hybrid constructs, called dextramabs, were found not only 
readily soluble in aqueous buffers, but at least as hydrophilic as the parental antibody trastuzumab, even when 
conjugated with eleven highly hydrophobic MMAE counterparts.  
The binding properties of all generated constructs were not affected, as demonstrated by comparable KD values 
on HER2-positive SK-BR-3 cells (unmodified trastuzumab: KD = 4.9 nM, dextramab (DAR 8): KD = 5.9 nM). Our 
synthetic dextramabs showed potent subnanomolar cytotoxicity (IC50 = 100 pM) in cell proliferation assays on 
HER2-positive SK-BR-3 breast cancer cells and no cytotoxicity on HER2-negative control cells in vitro. These site-
specifically assembled ADCs may combine the beneficial pharmacokinetic properties, as their protein 
counterparts are loaded with dextran, therefore possess higher hydrodynamic radius, with the possibility to 
attach a tailored number of payloads. Generally, our concept represents a promising approach for the 
generation of highly hydrophilic site-specific ADCs characterized by a high DAR. Follow-up animal studies will 
unveil if dextramabs hold promise for the novel class of ADCs with high potency, low immunogenicity and 
enhanced in vivo half-life. 
 
In the second investigation we studied applicability of dextran polysaccharide scaffold as carrier for apoptosis-
triggering payloads of diverse nature, which act by addressing distinct intra- or extracellular targets. Hence, 
additionally to the above-mentioned high-DAR ADCs we were focused at validating dextran as a platform for 
multimerization of cancer-relevant ligands.  
First, death receptor 5 (DR5) was chosen as a model target expressed on the cell surface. As it is activated by 
oligomerization/aggregation, we aimed at constructing a flexible scaffold able to bypass the reported need for 
spatial ligand orientation for efficient DR5-mediated cellular cytotoxicity. Thus, we designed a molecular 
architecture comprising a polysaccharide scaffold carrying the desired number of DR5 peptidic binders able to 
efficiently trigger apoptosis upon DR5 receptor clustering. Herein, apoptosis of cancer cells was mediated by 
multivalent binding to and clustering of a receptor located on the cell surface, which is in fact contrary to the 
first approach investigated in this work, which relied on a high number of a very potent cytotoxin that only upon 
internalization inhibits cell division by blocking the polymerization of tubulin. Thus, dextran was loaded with on 
average 11 or 13.4 peptidic binders, namely death receptor 5 targeting peptides (DR5TP). The resulting 
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constructs were found potent apoptosis-inducing conjugates possessing double-digit nanomolar half-maximal 
effective concentration (EC50) values on DR5-positive COLO205 colon cells and Jurkat T lymphocytes in vitro. 
Moreover, conjugation to glutamine 295 of an aglycosylated fragment crystallizable (Fc) fragment of a 
monoclonal antibody (mAb) by site-specific mTG-catalyzed conjugation resulted in constructs that showed 
selective DR5 binding upon flow cytometric analysis and further did not impair the potency of the generated 
multivalent scaffolds. In contrast, these protein-polysaccharide-peptide hybrids demonstrated higher potency 
in vitro (EC50 = 1.9 - 6.7 nM).  
Notably, in this approach binding is not mediated by the protein, but rather by the ligand-bearing dextran 
counterpart. Thus, addition of a second targeting moiety, e.g. application of a full-length antibody, would be an 
interesting prospective study that opens the possibility of bispecific targeting, which may result in enhanced 
safety and efficacy. Furthermore, the generated DR5TP-dextran and the Fc-bound counterparts were able to 
circumvent the mentioned need for spatial orientation of ligands due to additional flexibility provided by dextran 
scaffold. Our study further underlines the modularity of dextran as carrier for different payloads addressing 
various targets. In addition, this approach may help overcoming the reported off-target toxicity for multimeric 
high-affinity protein-based constructs, e.g. TAS266, by the application of low-affinity peptidic binders. This may 
lead to better tolerability in vivo, conditioned by lower retention on healthy cells expressing minor levels of DR5, 
which might be additionally improved by prospective bispecific targeting. 
 
The third part of this work was aimed at relieving the current lack of satisfactory overviews on mTG-mediated 
generation of homogeneous ADCs. Since most reviews dealing with ADCs cover a broad scope of topics, but 
usually very briefly, an in-depth comparative survey was highly required. However, a detailed overview of the 
factors influencing the resulting architectures in view of stability, potency, efficiency, etc. was still missing. A 
comprehensive summary of the reported strategies may enable tailoring of existing methods for mTG-promoted 
conjugation to the needs of particular research projects. On these grounds, the originated review was intended 
not only to enumerate the applied approaches for site-specific conjugation with respect to ADC assembly, but 
to map out the research groups and companies working on mTG-mediated generation of antibody-drug 
conjugates. Our review, gives a thorough overview of conjugation methodologies, addressed conjugation motifs 
or sites, applied cellular targets, linkers, and cytotoxic cargoes. Thus, it highlights pioneering routes and 
techniques, recent progress and remaining limitations of mTG-assisted assembly of ADCs. 
 
Furthermore, a study aimed at assessment of possibilities offered by dextran as a multivalency-promoting 
framework was performed. In a preliminary proof-of-concept study dextran was applied as a vehicle for multiple 
attachment of metal-chelating agents able to carrier valuable ions for radio-imaging or -therapy. Thus, dextran 
polymer was equipped with a desired number of a widely applied metal chelator 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). The assembled DOTA-dextran conjugates were able to 
carry 3.2 or 5,3 metal ions per polysaccharide chain, respectively, as shown by photometric analysis of the 
formed complexes with Cu2+. In vivo biodistribution studies in mice are currently ongoing. This proof-of-concept 
study should answer the question, whether these novel molecular hybrids are suitable for in vivo applications 
and whether conjugation to commonly applied binders (affibodies) that suffer from hydrophobicity and in 
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consequence poor solubility, aggregation and precipitation, results in beneficial properties. This approach 
further strengthens the presumption that dextran represents a promising modular scaffold for multivalent 
attachment and tailoring of diverse payloads.  
 Individuelle Beiträge zum kumulativen Teil der Dissertation  xii 
Individuelle Beiträge zum kumulativen Teil der Dissertation 
 
1) H. Schneider, L. Deweid, T. Pirzer, D. Yanakieva, S. Englert, B. Becker, O. Avrutina, H. Kolmar, Dextramabs: A 
Novel Format of Antibody-Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold, ChemistryOpen, 8 
(2019) 354-357. https://doi.org/10.1002/open.201900066 
 
Beiträge von Hendrik Schneider 
 
 - Initiale Idee und Projektplanung zusammen mit H. Kolmar. 
 - Durchführung des Großteils der Experimente. 
 - Verfassen des Manuskripts und Anfertigung aller darin enthaltenen Abbildungen. 
 
Der Anteil von Hendrik Schneider an genanntem Projekt belief sich auf insgesamt 80%. Die verbleibenden 20% 
verteilen sich auf L. Deweid, T. Pirzer, D. Yanakieva für Beteiligung am Experimentalteil. Des Weiteren auf 
S. Englert, B. Becker und O. Avrutina für kritisches lesen und korrigieren des Manuskriptes, sowie H. Kolmar für 
Projektkoordination. 
 
2) H. Schneider, D. Yanakieva, A. Macarrón, L. Deweid, B. Becker, S. Englert, O. Avrutina, H. Kolmar, 
TRAIL-inspired multivalent dextran conjugates efficiently induce apoptosis upon DR5 receptor clustering, 
ChemBioChem, 20 (2019), 3006-3012. https://doi.org/10.1002/cbic.201900251 (Marked as Very Important 
Paper, will be Front Cover in December, Issue 24), https://doi.org/10.1002/cbic.201900702 (Cover Picture) 
 
Beiträge von Hendrik Schneider 
 
 - Initiale Idee und Projektplanung 
- Literaturrecherche. 
- Durchführung des Großteils der Experimente 
 - Schriftliche Ausarbeitung des Manuskripts und Anfertigung aller darin enthaltenen Abbildungen. 
 - Design und Anfertigung des Front Covers von ChemBioChem Ausgabe 24 (Dezember) 
 
Der Anteil von Hendrik Schneider an genanntem Projekt belief sich auf insgesamt 80%. Die verbleibenden 20% 
verteilen sich auf D. Yanakieva, A. Macarrón, L. Deweid, B. Becker, S. Englert für Beteiligung am Experimentalteil, 
sowie O. Avrutina und H. Kolmar, die das Manuskript gelesen und konstruktiv korrigiert haben. 
 
ChemBioChem: According to the evaluation of the referees, the results reported in your article 
cbic.201900251R1 are of high scientific quality and your manuscript has therefore been marked as VIP (very 
important paper). Less than 10% of our manuscripts receive such a positive reviewer feedback. We think that 
the content of your article would be suitable for a front cover of the journal. Additionally, we recommend that 
 Individuelle Beiträge zum kumulativen Teil der Dissertation  xiii 
you tell the publicity/press department of your institute about your publication and the excellent reviews that 
it has received; a press release could be possible. 
 
3) H. Schneider*, L. Deweid*, O, Avrutina and H. Kolmar, Recent progress in transglutaminase-mediated assembly 
of antibody-drug conjugates, Analytical Biochemistry, 595 (2020), 113615. 
https://doi.org/10.1016/j.ab.2020.113615 
 
*Diese Autoren haben gleichermaßen zu diesem Projekt beigetragen. 
 
Beiträge von Hendrik Schneider 
 
 - Initiale Idee und Literaturrecherche. 
 - Schriftliche Ausarbeitung des Reviews und Anfertigung der darin enthaltenen Abbildungen. 
 
Der Anteil von Hendrik Schneider an genanntem Projekt belief sich auf insgesamt 40%. Der Beitrag von 
L. Deweid als Co-Autor belief sich ebenfalls auf 40%. Die verbleibenden 20% verteilen sich auf O. Avrutina und 
H. Kolmar für ihre Unterstützung bei der Ausarbeitung des Manuskripts und der Anfertigung der Abbildungen. 
Das genannte Manuskript wird sofort nach acceptance online im Rahmen des Special Issue „Transglutaminases 
in Translation – Novel Tools and Methods Impacting on Diagnostics and Therapeutics“ in Analytical Biochemistry 
einer Einladung des CEO von Zedira (Ralf Pasternack) folgend veröffentlicht werden. 
 
4) M. Baalmann,* L. Neises,* S. Bitsch, H. Schneider, L. Deweid, N. Ilkenhans, M. Wolfring, M. J. Ziegler, 
P. Werther, J. Wilhelm, H. Kolmar and Richard Wombacher, A bioorthogonal click chemistry toolbox for targeted 
synthesis of branched and well-defined protein-protein conjugates, (under review, chemRxiv. Preprint. 
https://doi.org/10.26434/chemrxiv.10743344.v1) 
 
Beiträge von Hendrik Schneider 
 
 - Beteiligung an der initiativen Projektidee 
- Beteiligung an der Durchführung der Experimente 
 - Beteiligung an der schriftlichen Ausarbeitung 
 - Beteiligung an der Ausfertigung der Abbildungen 
  
Der Anteil von Hendrik Schneider an genanntem Projekt belief sich auf insgesamt 15 %. Die verbleibenden 
85 % verteilen sich auf M. Baalmann, L. Neises, S. Bitch für ihre Beteiligung am Experimentalteil und zum 
Verfassen des Manuskriptes und an L. Deweid, N. Ilkenhans, M. Wolfring M. J. Ziegler, P. Werther, J. Wilhelm für 
ihre Beteiligung am Experimentalteil sowie H. Kolmar und R. Wombacher für Projektkoordination und 
Unterstützung beim Verfassen des Manuskripts. 
 Individuelle Beiträge zum kumulativen Teil der Dissertation  xiv 
 
#Diese Autoren haben gleichermaßen zu diesem Projekt beigetragen. 
 
5) L. Deweid, L. Neureiter, S. Englert, H. Schneider, J. Deweid, D. Yanakieva, J. Sturm, S. Bitsch, A. Christmann, 
O. Avrutina, H.-L. Fuchsbauer, H. Kolmar, Directed Evolution of a Bond-Forming Enzyme: Ultrahigh-Throughput 
Screening of Microbial Transglutaminase Using Yeast Surface Display, Chemistry – A European Journal, 24 (2018) 
15195-15200. https://doi.org/10.1002/chem.201803485 
 
Beiträge von Hendrik Schneider 
 
 - Beteiligung an der Durchführung der Experimente 
  
Der Anteil von Hendrik Schneider an genanntem Projekt belief sich auf insgesamt 10 %. Der Beitrag von L. 
Deweid für initiale Idee, Projektplanung, Durchführung des Großteils der Experimente, Verfassen des 
Manuskriptes und Abbildungen belief sich auf 75%. Die verbleibenden 15% verteilen sich auf L. Neureiter, 
S. Englert, J. Deweid, D. Yanakieva, J. Sturm, S. Bitsch und A. Christmann für ihre Beteiligung am Experimentalteil 
sowie O. Avrutina, H.-L. Fuchsbauer und H. Kolmar für Projektkoordination und Unterstützung beim Verfassen 
des Manuskripts. 
  
 Individuelle Beiträge zum kumulativen Teil der Dissertation  xv 
 
  
 
 
 
 
 
 
Des Weiteren bestätige ich, Hendrik Peter Günter Schneider, die Richtigkeit der obenstehenden prozentualen 
Angaben zur Beteiligung an sämtlichen genannten Veröffentlichungen, und erkläre nicht an der Begutachtung 
selbiger beteiligt gewesen zu sein. 
 
 
 
 
 
Datum:      Unterschrift: 
 
 
       _____________________________ 
          Hendrik Peter Günter Schneider 
 
 Introduction   1 
1. Introduction 
 
1.1. Cancer Treatment – A Brief Introduction 
Cancer comprises a group of diseases characterized by abnormal cell-division and -growth thus invading 
surrounding tissues and spreading around the body, which results in malignant neoplasia. Despite intensive 
research and obvious therapeutic progress, malignancies represent a major global health issue to date. Thus, 
cancer is ranked as the most crucial barrier to increase the life expectancy in every single country in the 21st 
century.[1] Furthermore, it represents the second leading cause of death in the United States with over 1.7 million 
new cases, over 600,000 new cancer-dependent deaths prognosed in 2019, and about 9.6 million deaths per 
year globally.[2, 3] 
In the beginning of the 1900s Paul Ehrlich introduced the concept of drugs to treat infectious diseases and the 
newly coined word “chemotherapy”, delineating it as the use of chemical compounds for disease treatment. 
Furthermore, he projected the idea of the “magic bullet” aimed at killing a harmful agent while leaving healthy 
tissues untouched.[4, 5] In the 1960s, combination of surgery and radiotherapy was acknowledged as standard 
cancer treatment.[4] However, only one third of treated patients were treated successfully as the applied 
therapies were not able to handle small metastases.[4] At that time, new research remarkably showed that a 
combination of classical methods with chemotherapy can lead to full cancer remission in patients with various 
tumors.[4] The first applied chemotherapeutic agents tested in humans comprised toxic nitrogen mustards, 
chlorambucil, and cyclophosphamide targeting DNA by alkylation (Figure 1).[6] Further, antifolates like 
methotrexate were introduced as higher proliferation rates for tumors treated with folic acid were observed.[6] 
Early in the following years chemotherapy became the predominant approach in tumor therapy.[6-8] Hence, a 
plethora of cancer targeting compounds was designed. Today, the majority of chemotherapeutics follow a non-
specific uptake through lipophilic interactions with the cell membrane of the tumor cell.[9] Usually, these 
compounds promote killing of rapidly dividing cells exhibiting higher proliferations rates.[6, 10] This is mediated 
by inhibiting microtubule function, DNA synthesis or protein function for example.[11] However, not only 
malignant cells are affected but numerous healthy ones, for example those from the epithelium, bone marrow 
and gastrointestinal tract.[6, 12] Additionally, DNA synthesis interfering nucleoside analogues (thioguanine, 
cytosine arabinoside), DNA interacting agents such as anthracyclines and actinomycin D, and tubulin targeting 
Vinca alkaloids derived from plants were utilized for cancer treatment (Figure 1).[6]  
Further, the combination of cytotoxins possessing different modes of action for tumor killing resulted in 
synergistic effects increasing the antitumoral efficacy while decreasing the overall cytotoxicity.[7, 8, 13] 
Additionally, generation of highly potent cytotoxins like DNA alkylators (e.g. pyrrolobenzodiazepine dimers, 
CC-1065, adozelesin) and tubulin inhibitors (e.g. dolastatin 10, dolastatin 15, maytansin, cryptophycins) evolved 
over the years.[6, 13] Unfortunately, these enormously potent cytotoxic agents lacked a sufficient therapeutic 
window conditioned by the development of resistance mechanisms and severe adverse effects caused by 
off-target toxicity due to the lack of selectivity.[6, 13-15] Furthermore, the discovery of oncogenes and 
tumor suppresser genes triggered the introduction of novel tumor-targeting drugs.[5, 16, 17] Being highly selective, 
these compounds target specific mutations originating from the cancerous cell.[5] By inhibiting kinases 
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responsible for proliferation or for blocking protein interactions, these agents led to severe improvements in 
selectivity.[5]  
 
 
Figure 1. Overview of chemotherapeutic agents. 
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Additionally, highly selective therapeutic monoclonal antibodies (mAbs) have gained success for the treatment 
of cancer after the observation of tumor-specific antigens located on the cell surface.[18-20] Being either 
overexpressed, solitarily expressed or even mutated on the surface of tumor cells,[19] these antigens comprise 
e.g. cell-surface proteins, glycoproteins, or carbohydrates.[6] High specificity of antibodies combined with their 
affinity to tumor antigens makes this class of molecules less off-target toxic compared to their small molecule 
chemotherapeutic counterparts.[18] In the last two decades successful antibody-based therapies for the 
treatment of hematological malignancies and solid tumors were established.[19] Thus, over 50 mAbs are currently 
undergoing evaluation in late stages of the clinical trials and at least 6-9 mAbs per year are expected to be 
approved, and about 70 of them are predicted to be marketed by 2020.[21, 22] These compounds either act as 
agonists or antagonists when bound to surface-exposed cell receptors, though modulating receptor-mediated 
signaling as applied for the marketed antibodies cetuximab and trastuzumab.[19, 23, 24] Further, these kind of 
biomolecules trigger Fc-mediated immune response, e.g. complement-dependent cytotoxicity (CDC), antibody-
dependent cellular cytotoxicity (ADCC, rituximab) and regulation of T-cell functions,[19, 25] as well as depletion of 
circulating tumor cells, antibody-dependent phagocytosis and apoptosis leading to cell death.[6] Following the 
first success of this class of compounds, improvement of effector functions, pharmacokinetics and 
immunogenicity via application of chimeric, humanized and fully human antibodies has been achieved.[19]  
To enhance tumor selectivity of chemotherapeutics, thus widening of the therapeutic window, the concept of 
antibody-drug conjugates (ADCs) evolved based on furnishing a mAb with potent cytotoxins.[6, 26] These novel 
compounds combined targeting, pharmacokinetics, and suitable biodistribution properties of mAbs with the 
potency of the conjugated cytotoxic small molecule.[26, 27] Following the approval of brentuximab vedotin and 
trastuzumab emtansin, more than 60 ADCs have currently entered clinical trials.[27] Further, the number of mAbs 
in phase III clinical trials increased from 26 to 52 from 2010 to 2017; currently over 230 mAbs are in phase II 
clinically studies.[22]. Interestingly, only one bispecific mAb is currently investigated in phase III studies, while 
twelve are investigated in phase II and three are in phase I/II.[22] The structure and functions of antibodies and 
ADCs will be described in the sections 1.3 and 1.4. 
 
1.2. From Innate to Adaptive Immunity 
The immune system is the host defense against different types of infectious pathogens of microbial, fungal, 
parasitic or viral nature constantly attacking vertebrates. Thereby, the innate or unspecific immune system acts 
as the first-line defense by identifying and destroying infectious pathogens.[28] The innate immune system 
comprises mechanic physiological barriers, among them the skin, the gastrointestinal tract bearing gastric acid, 
epithelia, the blood-brain barrier, and the mucus layer. Further germline-encoded host sensors called pathogen 
recognition receptors (PRRs) like toll-like (TLRs), RIG-I-like (RLRs), NOD-like (NLRs) and DNA receptors play a key 
role by recognizing pathogen-associated molecular patterns (PAMPs), that are correlated with commonly 
microbial pathogens.[29-31] Hereby, each receptor is able to bind to a variety of molecules conditioned by a broad 
intrinsic specificity.[32] These PRRs are expressed on cells of the innate immune system, e.g. dendritic cells, 
macrophages, and neutrophils (Figure 2).[29] The recognized bacterial PAMPs are mainly parts of the bacterial 
cell wall being structurally lipoproteins, lipopolysaccharides, peptidoglycans, or lipoteichoic acids, whereas viral 
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targets of the innate immune system are solely represented by viral nucleic acids.[29, 30, 32] Therein, differentiation 
between viral, bacterial and self-DNA is possible due to chemical modifications and structural unique features 
of the DNA.[30, 32] Binding of PRRs triggers several antimicrobial immune responses, like release of inflammatory 
cytokines, among them tumour-necrosis factor (TNF), interleukin-1β (IL-1β), IL-2 and IL-6, chemokines and type I 
interferons.[29, 32]  
 
 
Figure 2. Hierarchy of the vertebrate immune system. The innate immune system comprises first-line mechanic barriers and 
second-line internal defenses. And the resulting adaptive immunity represented by highly specific immune responses, e.g. antibodies. 
 
Furthermore, the innate immune system triggers the initiation of the adaptive immunity representing the 
second barrier of immunity that enables a broader and more selective response to infectious pathogens (Figure 
2).[33] Thus, generation of highly pathogen-specific B and T lymphocytes takes place, which employs antigen 
receptors that are not encoded in the germline.[34] A clonally diverse repertoire of unique antigen receptors 
located on lymphocytes represents the main feature of the adaptive immunity.[35] The binding diversity of these 
receptors is generated by somatic recombination that is mediated by the recombination-activating gene (RAG)-
protein-mediated encoding genes for the variable and constant fragment.[30, 36]. Gene conversion and non-
templated nucleotide addition as well as, in the case of B cells, somatic hypermutation further enhances 
diversity.[30, 36]  
Pathogen recognition of the adaptive immune system is achieved by multiple receptors with large soluble 
proteins – antibodies – among them. After activation by the respective cells, among them the dendritic ones 
and T lymphocytes, B cells differentiate to plasma cells and produce antibodies as humoral immunity.[33, 37] 
Following receptor-mediated endocytosis and intracellular degradation, antigen peptide fragments are 
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presented on the surface of B lymphocytes bound to major histocompatibility complex (MHC) class II.[32, 38] 
Recognition of these antigenic peptides by T-cell receptors (TCRs) of activated CD4-positive T cells leads to the 
secretion of cytokines that induce proliferation and differentiation of B cells to plasma cells secreting 
antibodies.[32] Additionally, some microbial pathogens like microbial polysaccharides can activate B cells directly. 
However, somatic hypermutation and isotype switching is dependent on the interaction with CD4+ T cells 
resulting in a less variable repertoire of antibodies.[32] The generated immunoglobulins, immunoglobulin M (IgM) 
and IgD are presented on the surface of naïve B cells.[39] Hereby, IgM represents the first isotype produced before 
isotype switching.[40] IgM builds a pentameric form comprising ten potential binding sites. It is able to recognize 
several phylogenetically conserved structures like proteins, nucleic acids, lipids, and carbohydrates.[31, 41, 42] 
However, affinity of these naïve antibodies is rather low. Hence, stimulation with antigen results in class 
switching of B cells into plasma cells which enables the production of high-affinity IgG, IgA, IgE and IgD 
counterparts (Figure 3).[39, 40, 43]  
 
 
 
Figure 3. Antibody classes: (A) pentameric IgM, (B) dimeric IgA, (C), IgG, (D) IgE and (E) IgD. modified from News Medical Life Sciences[44] 
 
This switch occurs upon antigen binding by a mechanism called class switch recombination (CSR) in combination 
with activation-induced cytidine deaminase (AID).[39] AID converts cytosine in the switch region to uracil resulting 
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in removal by DNA repair mechanisms and double strand breaks. Finally, replacement of the µ and δ heavy chain 
constant regions with γ, ε or α heavy chain constant regions occurs.[39, 45] The structure and function of antibodies 
will be described in the following section. 
 
1.3. Antibodies 
1.3.1. Structure and Function 
Antibodies represent a key element of the human adaptive immune system. These proteins are present either 
in a membrane-bound form called surface immunoglobulin and being part of the B-cell receptor or in form of a 
secreted protein only differing in a small part of the C-terminus of the heavy chain constant domain.[32] Being 
produced as glycoproteins, these biomolecules are able to selectively bind a target antigen. The heterotrimeric 
glycoproteins are further divided in five classes, called IgA, IgD, IgE, IgG and IGM, which differ by the constant 
domain of the heavy chains (Figure 4).[43, 46] These five classes comprise glycoproteins composed of 82-96 % 
protein and 4-18 % carbohydrate.[46] 
Among immunoglobulins, IgG is the most prevalent species accounting for 10-20 % of plasma proteins and 
subdivided in the four subclasses IgG1, IgG2, IgG3 and IgG4.[40, 46] These subclasses possess more than 90 % 
sequence identity but differ in terms of antigen binding, immune complex formation, complement activation, 
effector cell triggering, half-life, and placental transport.[46] IgGs are large Y-shaped molecules consisting of three 
equal-sized parts connected via a flexible linker called hinge region.[32] These homodimeric molecules are 
composed of two identical light chains with a size of approximately 25 kDa, and two identical heavy chains of 
55 kDa each (Figure 4).[47] The heavy chains are linked by disulfide bonds in the flexible hinge region and by non-
covalent interactions of the constant domains (CH3).[46] Further, the heavy chains are connected with the light 
chain by an additional disulfide bond. Each of these light chains consists of a variable domain (VL) which is 
C-terminally bound to one constant domain (CL) which can either be a λ- or κ-chain. In addition, each heavy chain 
of the molecule consists of one variable domain (VH) C-terminally linked to the CH1 which is further connected to 
the CH2 and CH3.[46] These domains form a characteristic fold bearing two antiparallel β-sheets yielding a roughly 
barrel-shaped structure called β-barrel and consisting of four ~110 residue long folds.[32] Antibody molecules can 
be further divided in the fragment crystallizable (Fc) consisting of two CH2-CH3 heavy chain dimers and a structure 
composed of VH, VL, CH1 and CL called fragment antibody binding (Fab) (Figure 4).[46] Interestingly, these antibody 
molecules can be fragmented applying digestive proteases, e.g. papain or pepsin, especially cleaving in the 
flexible hinge region[48]  
The variable domains of an antibody form the paratope responsible for the binding properties, whereas the 
constant domains mediate the effector functions. Two identical antigen-binding sites are generated due to 
symmetric structure of immunoglobulins.[32]  
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Figure 4. Schematic structure of IgG1 antibodies (A) and ribbon representation (PDB: 1HZH) (B). The homodimeric antibody consists of 
two identical heavy and light chains. The light chain consists of the VL which is C-terminally connected with one constant CL. The heavy 
chain consists of the VH C-terminally linked to the CH1, which is further linked to CH2 and CH3. The molecule comprises one Fc-fragment 
bearing a N-glycosylation pattern and two Fab fragments bearing the paratope facilitating antigen binding of the antibody. The VH and 
the VL together form the variable fragment FV.  
 
Binding is enabled by the complementarity determining regions (CDRs) located in the N-terminal variable 
domains of the heavy and light chains of the Fab fragments, each possessing three hypervariable loops 
(CDR1, CDR2 and CDR3).[32] The CDRs point out of the antibody framework and are neighbored by relatively rigid 
regions called FR1, FR2, FR3 and FR4.[32] Notably, the antigen binding site is formed by CDRs of VH and VL, thus 
binding is mediated by a combination of heavy and light chain. Hereby, the surface formed by the CDRs of the 
heavy and light chains builds a site to which the complementary formed antigen can bind. Hence, small 
molecules bind in small pockets or junctions, whereas proteins are bound by the interfaces that involve all 
CDRs.[32] The resulting non-covalent reversible binding is mediated by electrostatic forces, hydrogen bonds, Van-
Der-Waals and hydrophobic interactions or the combination thereof. Diversity of CDRs is generated through 
differential assembly of the Variable, Diversity, and Joining gene segments, known as V(D)J-recombination 
accomplished by developing B lymphocytes.[49] However, the Diversity gene segment is only assembled in VH 
domain. Somatic mutations are an additional feature that further enhances diversity.[30]  
The Fc fragment formed by the lower hinge region and the CH2 and CH3 domains is responsible for the effector 
functions of the antibody.[46] The Fc comprises the intrinsic binding sites for the Fcγ receptor (FcγR) and the 
complement-activation protein (C1q) located proximal to the hinge region in the CH2 domain.[46, 50] Binding to 
C1q and FcγR mediates complement-dependent cytotoxicity (CDC) or antibody-dependent cytotoxicity (ADCC), 
respectively, representing the effector functions.[19, 25, 46] The binding properties of FcγR and C1q are different 
for each IgG subclass conditioned by a varying structure of the hinge region (length and flexibility) and number 
of disulfide bonds.[46] Thus, the relative binding to the IgG subclasses can be ordered 
as: IgG3>IgG1>IgG4>IgG2.[46] In addition, the Fc fragment comprises a binding site for the neonatal Fc receptor 
(FcRn) located at the interface between CH2 and CH3 distinct from the binding sites for the FcγR and C1q located 
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near the hinge region in the CH2 domain.[46, 51, 52] The FcRn is responsible for the recycling of IgGs extending its 
half-life by reducing lysosomally degradation in endothelial cells.[51] Furthermore, it enables placental passage 
and the transport to mucosal surfaces.[46] Additionally, the Fc fragment bears an N-glycosylation site at the 
interface of the CH2 and CH3 domain of the heavy chain whose glycans also play a key role in FcγR binding upon 
introducing changes in the quaternary structure of the antibody.[46] Hereby, asparagine 297 (N297) of the heavy 
chain serves as anchor point for N-glycosylation.[53] This biantennary glycan is composed of a heptasaccharide 
consisting of a chain of two N-acetylglucosamine (GlcNAc) residues as core, bound to branched mannose 
polysaccharides and an additional GlcNAc residue.[53] Further, variable addition of a fucose or an additional 
bisecting GlcNAc and up to two galactoses or two sialic acids results in heterogeneity.[53] Glycosylation of the Fc 
affects FcγR-binding as well as the stability of the Fc as the interaction of the N297 glycan with the protein 
backbone stabilizes the Fc.[46, 54] Notably, core fucosylation of the IgG1-Fc N-glycans plays a role in 
FcγR IIIa-binding as non-fucosylated antibodies show higher affinity, thus compromising higher ADCC activity.[55] 
These compounds possessing selective targeting properties, pharmacokinetic properties represent a promising 
molecular scaffold for the equipment with cytotoxic payloads. Thus, resulting ADCs are promising candidates to 
selectively deliver an apoptosis-inducing small molecule to a chosen cellular target. These architectures will be 
addressed in the following sections. 
 
1.4. Antibody-Drug Conjugates (ADCs) 
1.4.1. Mechanism of Action of ADCs 
 
ADCs are composed of antibodies loaded with cytotoxic compounds aimed at their specific delivery to targeted 
cells.[13, 56] In these architectures, the beneficial characteristics of the antibody and a cytotoxic compound are 
combined leading to an enhanced therapeutic window, thus safer and more patient-friendly treatment.[7, 12, 13] 
To join an antibody and a cytotoxic payload, a special linker is used, either a cleavable or a non-cleavable one. 
Having entered the tumor tissue from the vasculature, the ADC is able to recognize and specifically bind a tumor-
overexpressed antigen on the cell surface of malignant cells (Figure 5).[18] Upon internalization following the 
endosome-lysosome pathway, the payload is released either via cleavage of the linker, or upon the antibody’s 
degradation.[13] Subsequently, the cytotoxic cargo diffuses into the cytoplasm to reach and interact with its 
target, e.g. tubulin or DNA, ultimately resulting in apoptosis of the malignant cell (Figure 5).[13] Envisioned to 
overcome the shortcomings of both compound classes, this strategy allows for the selective delivery of a potent 
drug omitting severe dose-limiting toxicity.[57] Further, the rather low efficacy of solitary antitumor antibodies is 
enhanced by addition of the cytotoxic payload.[20] To conclude, this targeted approach results in an immense 
widening of the therapeutic index in comparison to commonly applied chemotherapeutics. In the following 
sections a brief history of ADC development will be given. 
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Figure 5. Mechanism of action of antibody-drug conjugates for triggering apoptosis of tumor cells. (see section 4.3)modified from 
Lambert et al.[13] 
 
1.4.1. ADCs: A Brief History  
 
Chemotherapeutics kill rapidly dividing cells by inhibiting microtubule function, DNA synthesis, or protein 
function resulting in a dose-dependent therapeutic window (Figure 6).[58] However, this addresses not only 
malignancies, but also numerous healthy cells leading to severe adverse effects. To improve the therapeutic 
window, a cytotoxin with higher potency can be applied resulting in a lower minimum effective dose (MED), or 
the selectivity of a toxic compound can be enhanced to increase the maximum tolerated dose.[6] Thus, to bypass 
the narrow therapeutic window, researches turned to antibody-drug conjugates (ADCs).[58] These evolved from 
Paul Ehrlichs “magic-bullet” concept[5, 59] of a compound that selectively targets a disease-causing organism 
while simultaneously delivering a toxin.[60] Thus, ADCs are part of the “targeted therapy” concept, based on 
specific interference with molecular targets and pathways that are important for proliferation of cancer cells.[6]  
 
The first ADCs arose from the need to selectively and site-specifically deliver toxins to the tumor cell.[6] However, 
in the first half of the twentieth century only little progress was achieved, attributed to the difficult isolation of 
antibodies from animal and human serum and the fact that it was nearly impossible to produce a sufficient 
amount.[61] However, in 1958 Mathé et al. reported selective antiproliferation activity of a methotrexate 
conjugated to an antileukemia 1210 antigen antibody on L1210 mouse lymphocytic leukemia cells.[62] In the early 
1970s covalent conjugation and the choice of ligation method were reported to play a key role for ADC 
activity.[61, 63] Initially, anticancer drugs methotrexate, vinblastine, doxorubicin, and melphalan were examined.[6] 
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Early clinic attempts utilized KS1/4 antibody-methotrexate conjugates against non-small cell lung cancer and 
BR96 antibody-doxorubicin ones against metastatic breast cancer.[58] However, being able to localize at the 
tumor site, they had lack in therapeutic effectivity, obviously due to low selectivity and immunogenicity.[58] 
Indeed, the targeted antigens KS1 and BR96 were expressed on both tumor cells and healthy tissues, and used 
antibodies were of chimeric or murine nature, which triggered immune response.[58, 64-66]  
 
 
Figure 6. ADCs expand the therapeutic window. Selective delivery increases the percentage of administered toxin reaching the tumor, 
which lowers the medium effective Dose. Further, the targeted delivery of the cytotoxin increases the maximum tolerated dose as 
normal healthy tissue is reached. modified from Panowski et al.[58] 
 
The hybridoma technology established by Köhler and Milstein in 1975 became a major breakthrough in the field 
of ADC assembly as it addressed early problems in antibody production and purification.[6, 61, 67] Furthermore, 
recombinant technologies for the production of chimeric and – later – humanized antibodies ensured access to 
ADCs with reduced immunogenicity. The identification of different biomarkers, e.g. HER2 or the vascular 
endothelial factor (VEGF), and understanding of protein uptake mechanisms further advanced the success of 
ADCs.[61] Intracellular drug release from the protein-drug conjugate was identified as a key element for the 
design of effective ADCs.[61] Thus, linkers providing different cleavage options, e.g. enzyme-catalyzed hydrolysis 
(by peptidases and esterases), acidolysis, or intracellular glutathione-promoted reduction evolved.[58, 61] Fast 
development of these novel techniques resulted in the first marketed ADC – gemtuzumab ozogamicin 
(Mylotarg®) introduced by Wyeth for the treatment of acute myeloid leukemia.[68-70] In this construct, an 
anti-CD33 antibody was linked to a potent calichemicin derivative. However, in 2010 it was voluntarily 
withdrawn from the market due to issues regarding clinical safety and benefit.[6, 61] Notwithstanding, in 2017 it 
was approved for the treatment of acute myeloid leukemia applying a different dosage.[71] 
As only a limited number of ADCs is able to reach their cellular target, second-generation ADCs were loaded with 
extremely potent tubulin inhibitors, e.g. monomethyl auristatin E (MMAE),[72] monomethyl auristatin F 
(MMAF)[73] and maytansinoids (DM1, DM4)[74], or with DNA-targeting agents, like calicheamicins.[73, 75] In 
addition, pyrrolobenzodiazepine[76] and indolinobenzodiazepine[77] were applied. Lessons learned from these 
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early approaches were considered upon design of the second-generation ADCs and, finally, six constructs have 
reached the market. These are: brentuximab vedotin (Adcetris®, Seattle Genetics)[78, 79], polatuzumab vedotin-
piiq (Polivy™, Genentech and Roche)[80], trastuzumab emtansin (Kadcyla®, Genentech and Roche)[81, 82], 
inotuzumab ozogamicin and gemtuzumab ozogamicin (Besponsa®, respectively Mylotarg®, Pfizer)[68, 71, 83, 84], as 
well as moxetumomab pasudotoxas (Lumoxiti™, Immunotoxin, AstraZeneca)[85] all targeting hematologic 
malignancies or solid tumors. In addition, more than 60 ADCs are currently in clinical trials.[27] Most of these 
second generation ADCs are assembled by addressing endogenous thiols liberated by reduction of interchain 
disulfides, or by coupling to primary amines of lysine side chains. Obviously, heterogeneity is the feature of these 
compounds assembled by stochastic conjugation technologies.[7, 13, 26, 73] For instance, Kadcyla® is assembled by 
addressing lysines of HER2-targeting antibody trastuzumab with tubulin inhibitor DM1. However, 70 out of 88 
native lysines are accessible for conjugation, which results in inhomogeneity of ADC species.[86] Contrary, 
Adcetris® is assembled by ligation to partially reduced interchain disulfides resulting in a maximal reachable DAR 
of eight leading to reduced heterogeneity. However, this still results in a number of species comprising different 
DARs.[87]  
Therefore, novel third-generation ADCs rely on site-specific conjugations resulting in homogeneous constructs. 
They will be discussed in section 1.4.3 in detail. To convey a better understanding of the individual components 
of an ADC, these will be addressed in the following section. 
 
1.4.2. The Three Pillars of an ADC 
 
An antibody, a linker, and a cytotoxic agent represent the three key elements of an ADC (Figure 7).[7] The targeted 
antigen determines the choice of antibody that should be highly selective against it. Recently, the broad 
spectrum of cellular targets was delineated by a systemic database search that identified 87 ADCs against a total 
of 59 unique targets across 60 tumor (sub)types evaluated in clinical trials in 2017.[57] These are, for example 
numerous clusters of differentiation (CD19, CD22,CD25 CD30, CD33 etc.), tyrosine-protein kinase Met (c-MET), 
epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and tumor-
associated calcium signal transducer 2 (TROP-2 known as TACSTD2).[57] By implication, antigens highly 
overexpressed on malignancies but almost absent on the surface of healthy cells are favored as they result in a 
broader therapeutic window. However, the fact that some addressed antigens are expressed on healthy cells 
results in on-target, but off-tumor toxicity leading to severe adverse effects.[88, 89] For example, the most 
common adverse effect of EGFR blockade is skin toxicity.[88] Exemplarily, unwanted side-effects were observed 
in 80 % of patients medicated with cetuximab, among them acne-like rush, xerosis cutis, paronychia and 
fissuring, hair changes and mucositis.[88] Thus, a careful adjustment of the binding properties of an antibody is a 
prerequisite to achieve a balance between efficacy and toxicity of an ADC, depending on the expression levels 
of the desired antigen on tumors and healthy cells.[89-91]  
The second key element of an ADC is a cytotoxic payload that is covalently bound to an antibody. Conditioned 
by the hydrophobic character of most commonly applied toxins, DAR of ADCs normally does not exceed 3-4.[6, 7, 
13] Thus, the payload needs to be highly cytotoxic to reach efficacy at the given intracellular concentrations.[7] 
For instance, it is reported that about 106 molecules/cell of a moderately cytotoxic compound are needed to 
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efficiently kill tumor cells.[6] However, typically only 105 antigen molecules are present on the surface of the cell 
and can be recognized by an ADC. Moreover, inefficient internalization of the formed antigen-antibody complex 
and intracellular trafficking may additionally decrease ADCs effectiveness.[6] Moreover, only a small portion of 
administered ADC was reported to reach the targeted tumor.[6, 92]  
 
Figure 7. Representative schema of an ADC. Brentuximab vedotin (Adcetris®) is depicted as example. 4 linker-payloads are attached per 
antibody. Malimidocaproyl is applied for attachment to reduced hinge cysteines of the brentuximab. Valine-citrulline-p-aminobenzyl 
carbamate (Val-Cit-PABC) serves as protease cleavable linker (cathepsin)[92] and monomethyl auristatin E (MMAE) is applied as potent 
antineoplastic agent. modified from ADC Review[93] 
 
In general, the applied payload should be readily chemically modified and stable in circulation without affecting 
solubility. Notably, the number and hydrophobicity of the payloads have a major effect on the pharmacokinetic 
properties as species with high DAR may be problematic upon manufacturing and formulation due to enhanced 
hydrophobicity and poor solubility of the assembled ADCs.[13, 93] Strategies aimed at overcoming this issue are 
discussed in section 1.4.3.  
Applied toxins comprise antimitotic drugs, e.g. maytansins and auristatins, and DNA-addressing agents, among 
them calicheamicins, duocarmycins, and camptothecins.[6] Antimitotic drugs trigger apoptosis by inhibiting 
tubulin polymerization. As the assembly of microtubule represents a key step during mitosis, this class of 
compounds preferably kills rapidly dividing cells.[94, 95] If tubulin is bound close to the vinca alkaloid binding site 
a suppression of microtubule dynamics is provoked, thus cells are arrested in the G2/M phase ultimately leading 
to apoptosis.[6] The marketed ADCs Adcetris® (Figure 7), Polivy™ and Kadcyla® bearing vedotin, vedotin-piiq, and 
emtansin, respectively, comprise this class of cytotoxins. In contrast, DNA agents work by intercalating, 
crosslinking or by alkylation of DNA. Hence, these compounds are able to kill proliferating and non-proliferating 
cells. Calicheamicins, for example, bind tightly to the minor groove resulting in DNA double-strand breaks that 
ultimately lead to cell death.[6, 96] In contrast, duocarmycins and indolinobenzodiazepine pseudodimers act by 
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alkylation of DNA, which also triggers cellular apoptosis.[77, 97] In contrast, dimers of pyrrolobenzodiazepines 
(PBD) crosslink DNAs.[76] The marketed ADCs Besponsa® and Mylotarg® are loaded with a calicheamicin 
derivative (ozogamicin) that primarily mediates double-strand breaks. 
The third vital component of an ADC is a linker. This structural element enables covalent attachment of an 
antibody to the cytotoxic compound with an option to be cleaved under particular conditions and also has a 
certain influence on the ADCs properties. First, the linker needs to be stable in plasma to omit premature release 
of cytotoxin, resulting in off-target toxicity and narrowing of the therapeutic window.[60] Second, the linker 
should if possible voluntarily release the payload after reaching the target cell.[60] As mentioned above, the 
applied payloads are as a rule highly hydrophobic, thus a linker of the same nature could further raise problems 
due to aggregation and recognition by multidrug resistance (MDR) transporters.[60]  
Applied linkers can be categorized in two classes: cleavable and non-cleavable linkers. The latter hold integrity 
under physiological conditions, therefore payload release depends on lysosomal degradation of the whole 
construct.[60, 98] As a result, an additional amino acid from the antibody is still connected with the toxin after 
degradation.[60] This type of linkers is used for the assembly of marketed ADC Kadcyla®.[60]  
The class of cleavable linkers comprises protease-, pH-, and redox-sensitive ones. For example, being 
overexpressed in various cancer cells, cysteine protease cathepsin B is able to readily cleave after a 
valine-citrulline (Val-Cit), phenylalanine-lysine (Phe-Lys), or valine-alanine (Val-Ala) motif.[11, 99] Among the 
cleavable linkers, the most successful one comprises a Val-Cit motif accompanied by a self-immolative spacer, 
for example p-aminobenzyl carbamate (PABC) to enable a traceless toxin release.[11] This linker is applied in 
marketed ADC Adcetris®.[78, 79] Additionally, β-glucuronide linkers are utilized for an ADC assembly.[98] Hereby, β-
glucuronidase present in lysosomes is responsible for toxin release. Thus, cleavage occurs by lysosomal 
processing followed by a 1,6-elimination of the spacer resulting in release of the free drug.[98, 100] A major 
advantage of this linker is its polarity that has benefits in terms of aggregation and solubility.[98]  
Acid-labile linkers, e. g. hydrazones, are readily cleaved after internalization following the endosome-lysosome 
pathway as lower pH of the endosome (pH 5-6) and lysosome (pH 4.8) is sufficient for effective toxin release.[11] 
This linker strategy is used for the marketed ADC Mylotarg®.[68-70] However, ADCs comprising this type of linkage 
bear the potential of undesired payload release under physiological conditions as hydazone hydrolysis has been 
reported already at pH 7.4 (37 °C).[101] In contrast, redox-sensitive linkers rely on higher cytoplasmic 
concentration of glutathione (up to 1000-fold) compared to the extracellular environment.[98] Thus, a disulfide 
bond is incorporated at the linker that is stable in circulation, but is broken after internalization.[60, 98] 
In addition, the attachment site of the cytotoxic compound is important for the pharmacokinetic properties, e.g. 
half-life, stability, clearance of an ADC. This issue will be discussed in the following sections. 
 
1.4.3. Site-Specific ADCs  
 
Site-specific conjugation methods were introduced to overcome heterogeneity of ADCs towards an improved 
therapeutic window compared to the classical statistically conjugated counterparts.[102] These methods led to 
more homogenous ADC, which not only simplified purification but paved the way for a better understanding of 
the effect of the conjugation site on overall ADC properties. Thus, most of the third-generation ADCs rely on 
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conjugation methods that address distinct ligation sites. These methods can be divided in two main classes, the 
chemical and the enzymatic ones. Numerous approaches were applied to introduce reactive moieties, among 
them glycoengineering,[103-108] incorporation of additional cysteine residues (e.g. Thiomab®, Figure 8),[109-112] 
selenocysteines[113], or non-natural amino acids,[114-116] re-bridging of natural thiols,[87, 117] metallopeptide-based 
catalysis,[118] redox-based methionine bioconjugation[119], as well as autocatalytic attachment of the toxin to a 
reactive antibody’s lysine.[120] Subsequently, the chemical handles can be addressed by different payloads 
following diverse procedures. For instance, the Thiomab® technology relies on two genetically introduced 
additional cysteine residues accessible for toxins equipped with a maleimide handle, thus leading to highly 
homogenous ADCs comprising a DAR of 2 (Figure 8).[11, 110] Further, genetic incorporation of a non-natural amino 
acid was applied to introduce carbonyl or azide moieties for subsequent reactions to form oxime- or triazole 
conjugates, respectively.[11] 
 
Figure 8. Scheme of Thiomab® ADCs. Additional genetically incorporated thiols are accessible reactive handles for conjugation of toxins 
equipped with maleimide moieties. 
 
Furthermore, site-specific conjugation applying numerous enzymes were utilized to equip an antibody with a 
chosen payload. These enzymes comprise tubulin tyrosine ligase (TTL),[10, 121] formylglycine-generating enzyme 
(FGE),[122, 123] SpyLigase,[124] phosphopantetheinyl transferase,[125] sortase A,[126-128] mushroom tyrosinase[129] and 
microbial transglutaminase (mTG).[130] The respective procedures rely on one-step enzymatic or two-step 
chemo-enzymatic approaches for ADC assembly. Hereby, genetically incorporated recognition motifs located at 
distinct sites of an antibody were site-specifically addressed by the respective enzyme of choice to introduce 
either a reactive handle or the cytotoxic payload directly. For instance, Sortase A is capable of catalyzing the 
ligation between an LPXTG recognition motif and an N-terminal oligoglycine substrate in the presence of calcium 
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ions.[126] Hence, incorporation of a short recognition motif, exemplary at the C-terminus of the heavy chain, 
results in an antibody that can be easily conjugated with a payload in a site-specific manner.  
All the above-mentioned approaches were successfully applied for ADC generation possess distinct advantages 
and certain drawbacks. Reviews delineating the current status of site-specific ADCs in detail can be found 
elsewhere.[10, 131] mTG-mediated conjugation relevant for this work will be discussed in the following sections in 
more detail. 
 
1.4.4. Transglutaminase  
 
Transglutaminases (TGs) belong to the class of protein γ-glutamyltransferases found in microorganisms, plants, 
invertebrates, amphibians, fish, and birds.[132] This enzyme facilitates pH-dependent formation of an isopeptide 
bond between a primary amine and a glutamine residue under release of ammonia resulting in γ-carboxamides 
(Figure 9).[130, 133] These two counterparts can be located both in a protein or a peptide.[132] In the first step, an 
active thioester is formed by reaction of the sulfhydryl group of the cysteine located in the active site of the 
transglutaminase and the acyl portion of the glutamine substrate. Subsequently, the acyl acceptor, which can 
either be water or a primary amine, reacts with the formed active thioester resulting in either deamidation or 
crosslinking (Crosslink I), respectively. In addition, reaction of the active thioester with a polyamine, e.g. 
spermine, or the ε-amino group of lysine generates a new primary amine bearing species that can be further 
crosslinked (Crosslink II) by TG.[132] Interestingly, TGases comprise an intrinsic specificity towards the applied 
glutamine residue, whereas a broad variety of amine-containing acyl-donors is accepted.[134] 
 
Figure 9. Mechanism of action of transglutaminases. The protein- or peptide-bond glutamine side-chain are covalently cross-linked to 
the lysine counterparts. The formation of an isopeptide bond is accomplished under the release of ammonia. modified from Schneider et al. see 
section 4.3 
 
In nature, this mechanism is used for the conjugation of the glutamine side chain as acyl donor and the ɛ-amino 
group of lysine as acyl acceptor, to intra- or intermolecularly crosslink proteins.[132] Further, in multicellular 
organisms the generated isopeptide bonds add strength to tissues and increase their resistance to 
degradation.[130, 132] To date, different mammalian transglutaminases (TGases) are known, among them blood 
coagulation factor XIIa, keratinocyte TGase, epidermal TGase, tissue TGase, prostate TGase, TGase X/Y/Z and 
transglutaminase 2 (TG2). TG2, for example, crosslinks proteins on the outer surface of the squamous 
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epithelium.[130, 132, 133] In contrast, blood coagulation factor XIIa catalyzes crosslinking of fibrin molecules during 
blood clotting.[133, 135] Furthermore, bacterial transglutaminases (mTGs) have been discovered by thorough 
screening of different microorganisms.[130] These transglutaminases catalyze the same reactions, even lacking 
sequential or structural homology.[130]  
However, not all of these TGases are suitable for biotechnological applications.[133] Thus, mTG derived from the 
Gram-positive actinobacterium Streptomyces mobaraensis comprising good reactivity combined with stability 
represents the most applied TGase.[133] Exemplarily, it is applied in food processing where it acts as natural glue 
to texture meat and dairy products, for half-life extension by PEGylation of protein drugs, surface immobilization 
of proteins, and to covalently attach nucleic acids to proteins (Figure 10).[136] 
 
 
Figure 10. Overview of biotechnological and industrial applications of microbial transglutaminase. adapted from Schneider et al. see section 4.3 
 
1.4.5. ADCs Assembled under mTG Catalysis 
 
The need for the generation of homogenous ADCs has placed mTG in the focus of intensive research. Thus, 
numerous approaches towards covalent attachment of a desired payload to an antibody were carried out. First 
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approaches aimed at modifying native antibodies resulted in poor modification of lysine residues with 
glutamine-containing peptides and nearly no modification when glutamine sites were addressed.[137] However, 
the observation that genetic aglycosylation significantly enhanced labeling paved the way for mTG-mediated 
assembly of ADCs.[137] Consequently, in the following years either genetically aglycosylated or enzymatically 
deglycosylated antibodies were applied to site-specific ligate different payloads (Figure 11). A second milestone 
is engineering towards incorporation of glutamine-bearing motifs that are specifically recognized by mTG. In 
comparison to Sortase A, these motifs can also be introduced at internal positions highlighting the flexibility of 
mTG-based approach.[138] Thus, the numerous internal or terminal positions were examined regarding stability, 
toxicity, and efficacy of the generated ADCs.[138] 
 
 
Figure 11. Transglutaminase-addressable antibodies. (top) Native, glycosylated antibodies are no substrate of mTG. (bottom) 
Strategies for transamidation: (left) genetic incorporation of specific recognition motif; (middle) genetic or enzymatic removal of the 
CH2 glycan moiety to expose Gln295; (right) engineering of reactive lysines in surface exposed areas or addition of C-terminal residues 
to prevent Lys447 from intracellular processing. modified from Schneider et al. see section 4.3 
 
Besides addressing native or engineered glutamine residues of the antibody, natural or engineered lysines were 
examined as conjugation site for the generation of ADCs.[139, 140] Hence, lysine-bearing recognition motifs or 
solitary lysines were genetically incorporated. Further, introduction of additional amino acids at the C-terminus 
enabled labeling at lysine 447 by preventing its intracellular enzymatic cleavage resulting in minimal mTG 
recognition tags.[139]  
Besides direct conjugation with a cytotoxic compound, chemo-enzymatic two-step procedures were 
investigated (Figure 12). Herein, in the first step amine-bearing chemical handles, like DBCO, BCN or azides were 
introduced and used for payload conjugation in the second step.[141-144] This procedure combining site-specificity 
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of mTG catalysis with orthogonal chemistry displays a modular and convenient method for the assembly of ADCs. 
These site-specific procedures not only result in homogeneous and reproduceable ADCs, but also permit to 
examine the influence of attachment site, linker and the payload itself.[138] Thus, numerous approaches applying 
ADCs assembled under mTG catalysis were reported, which were aimed at improving therapeutic properties of 
the generated ADCs. These are the increase of DAR, enhanced lysosomal trafficking, linker stability, and 
modulation of parental antibody affinity, for example. A more detailed insight into the current status of site-
specific ADCs assembled under mTG catalysis can be found in the review presented in the cumulative section 
(section 4.3).  
 
 
Figure 12. Exemplary chemoenzymatic two-step procedure for mTG-mediated ADC assembly. First, an amine-bearing chemical handle 
is introduced that is subsequently used for payload attachment.  
 
1.5. High-DAR ADCs 
As aforementioned, the applied cytotoxins in the context of ADCs need to be highly potent to be efficient at the 
given intracellular concentrations.[7] Further, inefficient internalization and intracellular trafficking additionally 
decrease efficacy of the ADC.[6] Thus, increasing cytotoxicity of the payload or arming the ADC with a higher 
number of toxins per antibody were the obvious choices to enhance efficacy of an ADC. Trial-and-error 
approaches over the last decade led to the conclusion that toxins with potencies in the sub-nanomolar range 
are required.[145] However, the majority of applied potent cytotoxic drugs is highly hydrophobic, which may 
promote aggregation and enhanced recognition by MDR transporters.[13, 60] As the number, site, and 
hydrophobicity of the conjugated toxin strongly influences stability, pharmacokinetic properties and efficacy of 
ADCs, a careful design is required to develop an effective ADC for tumor treatment.[102, 138]  
In a comparative study addressing potency and safety of conventional thiol-maleimide conjugates in 
dependence of their DAR, Hamblett et al. showed that a DAR 4 anti-CD30 ADC was superior to a DAR 2 and 
DAR 8 ADC if hydrophobic MMAE was used as a payload.[146] The DAR 8 ADC possessed poor pharmacokinetic 
properties, enhanced toxicity and displayed a lower therapeutic index in mice.[146] Thus, the authors concluded 
that drug loading is a key design parameter for ADCs and a drug loading of 2-4 may yield the optimal therapeutic 
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window. Further, Sun et al. concluded that very high-DAR, thus more hydrophobic, ADCs suffer from decreased 
efficacy likely due to faster liver-mediated clearance.[147] Therefore, maytansin-based ADCs comprising a DAR of 
3-4 were chosen for further clinical evaluation. However, higher-DAR ADCs were still considered for tumor 
antigens with low expression levels or inefficient intracellular processing.[147] DNA alkylating agents like 
pyrrolobenzodiazepines (PBDs) represent another class of clinically relevant toxins, found to be even more 
potent, which limits the typically DAR of ADCs comprising these class toxins[145, 148] In addition, high-DAR ADCs 
may enable the application of milder toxins.[145]  
Besides the obvious progress in the filed of ADCs, achieving a high DAR without affecting hydrophilicity is still a 
major challenge. To that end, several approaches relying on more hydrophilic payloads or linkers were applied, 
among them e.g. a short polyethylenglycol (PEG) chains. Using this strategy, two ADCs targeting either Trop-2 
(IMMU-132) or CEACAM5 (IMMU-130) were assembled bearing the hydrophobic DNA topoisomerase inhibitor 
SN-38 with an average DAR of 7.6 and 7.5, respectively. Hereby, conjugation proceeded by addressing reduced 
cysteine thiols of antibodies by maleimide-bearing payloads.[149, 150] Daiichi Sankyo reported an ADC where a 
toxic exatecan derivative was assembled with an antibody via an enzymatically cleavable peptide linker (GGFG) 
equipped with a self-immolative linker with an aminomethyl moiety and bearing at the C-terminus an additional 
hydrophilic group.[151, 152] A DAR 8 ADC targeting HER2 revealed excellent tumor activity against 
T-DM1-insensitive and in HER2-low expression models.[152]  
Researches from Seattle Genetics applied more hydrophilic polyethylene glycol- (PEG)-bearing branched linkers 
to generate DAR 8 ADCs with larger therapeutic index (TI).[153] Hereby, excess tris(2-carboxyethyl)phosphine) 
TCEP was applied to fully reduce hinge disulfides. This approach was further optimized by evaluating the length 
of different PEG chains, whereby ADCs comprising branched PEG12 linker arose as lead candidates.[154] In another 
approach addressing reduced interchain disulfides, Seattle Genetics developed ADCs carrying multiple payloads 
applying orthogonal cysteine protection and PEGylated linkers to site-specifically conjugate each drug.[155] This 
approach opens avenue for the screening of dual-drug ADCs and presumably may lead to synergistic effects, 
thus improved activity. Furthermore, Mendelsohn et al. from Agensys introduced more hydrophilic pyridine 
derivatives of auristatin, called MMAPYE. These were assembled to ADCs by maleimide conjugation to reduced 
interchain disulfides and may enable overcome known drawbacks of hydrophobic payloads.[156] A similar 
approach by Satomaa et al. made use of more hydrophilic auristatin glycoside payloads combined with 
conjugation to reduced interchain disulfides.[157] Obviously, auristatin-D-glucuronide (MMAU) represents a novel 
promising hydrophilic payload for the application in context of ADCs.  
Further, Sanofi reported PEG-containing multivalent drug linkers applying more hydrophilic MMAD (compared 
to MMAE) as payload to address reduced interchain disulfides resulting in potent ADCs comprising DARs of up 
to 10.8.[158] In addition, a novel approach by Gupta et al. relied on platinum(II)-based linker for efficient 
interchain cysteine re-bridging.[159] These linkers were found to improve stability compared to traditional 
maleimide-linked ADCs. Furthermore, they were equipped with PEG chains to reduce the overall hydrophobicity. 
Besides addressing reduced interchain disulfides, the introduction of site-specific conjugation methods enabled 
the decoration with payloads at a desired site of an ADC. Thus, a comparative study by researches from 
Pfizer/Rinat showed that high-DAR ADCs site-specifically assembled under mTG catalysis can overcome the 
previously reported limitations of conventionally assembled ADCs.[102] As a high number of hydrophobic 
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payloads in proximity showed lower in vivo exposure, the authors concluded that the conjugation site is a major 
influential factor for in vivo exposure.[102] A minimization of solvent accessibility of the hydrophobic payloads 
was recognized as key element in the assembly of ADCs.[102] Notably, even though all of these approaches yielded 
high-DAR ADCs, none was able to fully shield the hydrophobicity of the conjugated toxin resulting in an ADC at 
least as hydrophilic as the unmodified parental antibody. 
Moreover, numerous approaches emerged aimed at half-life extension and enhanced hydrophilicity of proteins, 
which apply both chemical methods and genetical engineering. PEGylation, conjugation to dextran 
polysaccharide or recombinant PEG mimetics like XTEN or PAS, HESylation, polysialylation, HAylation, N- and O-
glycosylation, lipidation, and fusion with albumin for enhanced FcRn-mediated recycling are only a few to be 
mentioned.[160] Despite the fact that not all of them were used for ADC assembly, various polymeric multivalent 
linker systems able to carry the desired number of payloads were introduced. In 2005, Yurkovetskiy et al. applied 
a degradable poly-1-hydroxymethylethylene hydroxymethyl-formal (PHF) as acyclic mimetic of polysaccharides 
and alternative to PEG.[161] These polyacetals comprise pH-sensitive acetal groups stable in the extracellular 
environment (pH 7-7.5), but cleavable at the acidic pH of the intracellular vesicular compartment.[161] PHF can 
be chemically assembled or accessed by complete lateral periodate-mediated cleavage of dextran B-512. 
Periodate oxidation of the 1-6 polyglycoside followed by borohydride reduction gave rise to polyals with pendant 
hydroxymethyl groups and vicinal glycol groups (Figure 13).[161-163]  
 
Figure 13. Fleximer ®. A Schematic representation of poly-1-hydroxymethylethylene hydroxymethyl formal (PHF) (A), PHF-glutaric acid 
(B) and PHF equipped with toxin and thiols for antibody conjugation (C).modified from Yurkovetskiy et al.[163] 
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Subsequently, decoration with glutaric acid through esterification gave rise to a polymer loaded with multiple 
moieties addressable towards amide-bond formation with the amine-bearing N-(3-hydroxypropyl)vindesine 
alanine (NH2-Ala-HPV ) and a bidentate linker bearing a protected thiol.[163] Both moieties were coupled 
stoichiometrically. After deprotection of the thiol, the Fleximer®-toxin conjugate was stoichiometrically coupled 
to either a maleimide-bearing trastuzumab or rituximab assembled by standard succinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC) procedure. This procedure yielded ADCs comprising DARs 
of up to 20 and revealed single digit nanomolar IC50 on different HER2-positive cell lines and effective tumor 
growth inhibition in vivo using HER2(+++) NCI-N87 human gastric cancer and BT-474 breast cancer xenograft 
models.[163]  
The authors concluded that the high hydrophilicity and polyvalency of the polymer enabled the generation of 
high-DAR ADCs without compromising the physicochemical and pharmacokinetic properties. Notably, neither 
SDS-PAGE nor chromatographic analysis, e.g. hydrophobic interaction chromatography (HIC) or size-exclusion 
chromatography (SEC), elucidating hydrophilicity was performed in this study to confirm the success of two 
stoichiometrically controlled reactions. Notwithstanding, potent high-DAR ADCs were achieved paving the way 
for the application of milder toxins in a higher number. 
Furthermore, an additional improved polymer-based ADC based on Dolafelxin® platform was introduced by 
Mersana.[164] The assembled ADCs comprised a high load of auristatin F-hydroxypropyl amide (auristatin F-HPA), 
a synthetic analogue of dolastin 10, linked to the Fleximer® scaffold conjugated to a HER2-targeting antibody. 
Hereby, the ADC, called XMT-1267, was assembled by addressing reduced interchain cysteines resulting in less 
heterogeneity. However, incorporation of thiol groups onto Fleximer® was still performed in a stoichiometrical 
manner, thus yielding heterogenous species with different numbers of toxins and Fleximers® conjugated per 
antibody. Nevertheless, this procedure revealed a polymer-dependent stabilization of the reduced antibody 
which is achieved by formation of interchain bridges between the polymer backbone and the antibody’s 
thiols.[164] Furthermore, prolonged plasma half-life and tumor specific accumulation was reported for this ADC 
featuring a DAR of 20. In addition, tumor growth inhibition in BT-474 xenograft models was observed applying 
a low dose of 2 mg/kg.[164]  
In addition, N-(2-hydroxypropyl)methacrylamide (HPMA) was reported as polymeric scaffold for the generation 
of high-DAR ADCs. For instance, an approach by Zhang et al. based on rituximab (RTX) and HPMA copolymer-
epirubicin.[165] Hereby, epirubicin was incorporated onto HPMA by a controlled living polymerization resulting in 
a well-defined polymer-drug conjugate bearing a single maleimide for antibody conjugation. Thus, ADCs 
targeting CD20 were assembled by conjugation to reduced interchain cysteines of the parental antibody. 
Depending on the average number of conjugated polymers (3.1 - 6.5) the DAR of the generated ADCs varied 
from 20.6-42.9, respectively. Interestingly, even the ADCs comprising the highest DAR were found soluble in 
water and no aggregation was observed. However, assembled ADCs revealed a polymer ratio-dependent 
decrease of affinity. Thus, a conjugate equipped with an average of 3.1 polymers retained 50 % of parental 
binding affinity, whereas that equipped with an average of 6.5 only retained 30 % of binding affinity. In an in 
vivo Ramos xenograft model on CD20-positive NOD SCID mice the DAR 20 ADC was found superior compared to 
the combinations of rituximab with HPMA-epirubicin respectively solitary epirubicin. Furthermore, a non-
binding HPMA-epirubicin ADC was found non-toxic.[165]  
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1.6. Dextran 
 
Dextran is a naturally occurring polysaccharide. Today, different polymers of this class are used in biochemical 
applications. In recent years, numerous approaches applying polysaccharides like cellulose, starch, chitosan or 
dextran were developed. These natural polymers differ by the backbone sugar, linkage and the extent of 
branching within the polymer chain. Thus, cellulose is connected by β-D-glyosidic bonds of glucose, chitosan is 
composed of randomly distributed β-D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine, whereas 
dextran and starch are linked by α-D-glycosidic bonds of glucose. Due to the structure of these polysaccharides, 
chitosan, starch and cellulose are only poorly soluble in water. In cellulose and chitosan every sugar monomer 
is rotated by 180 ° with respect to its neighboring monomers promoting the formation of intra- and 
intermolecular hydrogen bridges and thus restricting water solubility. In contrast, starch consists of roughly 25 % 
of almost linear amylose and of 75 % highly branched amylopectin.[166] Hereby, the intrinsic branching results in 
week solubility in water. The mainly linear dextran polysaccharides with minimal branching ratio are good water-
soluble and rather homogen.  
Dextran was first studied a hundred years ago when its high viscosity caused trouble in the beet-sugar 
industries.[167] This α-glucan is mainly produced by bacteria belonging to the order of Lactobacteriaceae, family 
streptococcaceae, genus Leuconostoc, species L. mesenteroides (Betacoccus arabinosaceous) and L. dextranicum 
when cultured on sucrose as carbon source.[167-169] However, to some extent it is chemically synthesized from 
levoglucosan (1,6-anhydro-β-D-glucose) via a cationic ring-opening polymerization.[170, 171] The enzyme 
polymerizes the glucose moiety of sucrose to dextran under the release of the fructose monomer.[168, 172] The 
proposed mechanism for L. mesenteroides B-512 F is described as follows. In a first step dextransucrase bearing 
two sucrose binding sites and one acceptor binding site forms two covalent glucosyl-enzyme complexes (Figure 
14).[172] In the second step a nucleophilic attack of the hydroxyl group located at the non-reducing end of the 
acceptor to C-1 of one of the two glucosyl residues that are covalently bond to the enzyme takes place.[172] 
Several sugars, like maltose or isomaltose, can inhibit dextran synthesis and yield acceptor products (Figure 
14).[172] Repetition of step two leads to the formation of dextran polysaccharide. However, a complete 
knowledge of the actual structure of the active site is still missing, as no experiment could give evidence that a 
distinct acceptor binding site exists.[173]  
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Figure 14.Proposed mechanism for the enzymatic polymerization by dextransucrase from NRRL B.512F resulting in dextran with minimal 
α-1,3-branching.modified from Plou et al.[172] 
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The central structure of dextran consists of α-1,6-glycosidic linkage with some degree of branching.[174] For 
solubility of dextran the degree of branching is a key element as higher branched dextrans are poorly water-
soluble.[175] Therefore, dextran from Leuconostoc mesenteroides B-512 is of special interest, as it is characterized 
by a content of 95 % α-1,6-glycopyranosidic linkages and only 5 % of 1,3-linkages (Figure 15).[160, 174, 175] These 
1,3-linkages are attachment points for side chains. 85% of these comprise only one or two glucose residues, 
whereas the remaining 15% have an average length of 33 glucose units.[160, 174, 175] Other dextransucrases 
originating from different bacteria produce dextran with different percentages of branching. Exemplary, 
dextransucrase from L. mesenteroides B-1299 assembles dextran exhibiting a higher degree of branching and 
additional α-1,2 branching.[172] Additionally, dextran differs in the degree of polydispersity, which has severe 
effects on its behaviour in vivo.[175] However, today dextrans with a broad range of molecular weights and narrow 
polydispersity (PDI) are readily commercially available.  
 
 
Figure 15. Structure of dextran from Leuconostoc mesenteroides B512. (A) The repeating glucose units are mainly connected by α-1,6-
glycopyranosic linkages with 1,3-linkages as attachment points for branching. The degree of branching is approximately 5 %. Herein, 85 % 
of these branches comprise only one or two glucose residues, whereas the remaining 15 % have an average length of 33 glucose units. 
(B) Equilibrium of the reducing end of dextran allowing for addressing the orthogonal aldehyde moiety. 
 
The almost linear structure and its good water solubility makes dextran a promising scaffold for payload 
conjugation and linkage to the proteins of interest. Commercial dextran with a molecular weight of 70000 is 
applied in solution to restore and to maintain the blood volume for the treatment of shock, hemorrhage and 
burns.[174] Further, dextran 40000 is used to improve capillary flow and for the treatment of vascular 
occlusion.[174] In the United States it is clinically approved and used as 6 or 10 % aqueous solutions containing 
either 40000 or 70000 kDa dextran for blood-flow enhancement or as plasma-volume expander.[175] 
Additionally, the FDA has granted dextran the status GRAS meaning “generally regarded as safe”.[160]  
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Dextrans can be depolymerized by dextranases present in various organs of the body, among them spleen, 
kidney, liver, and the lower part of the gastrointestinal tract, with liver and spleen being the predominant 
locations.[174, 175] However, in vitro studies showed that modification of dextran reduced depolymerization.[174, 
176, 177] Furthermore, biodistribution studies with fluorescein-labeled dextran revealed that its tissue disposition 
depends on molecular weight. Thus, low-molecular-mass dextrans are excreted unchanged in the urine, whereas 
dextrans with higher molecular mass show accumulation in the liver and the spleen.[175, 178-180] It should be noted 
that although dextran-reactive antibodies have been involved in anaphylactoid reactions,[181-183] and antibodies 
against chicken serum albumin-dextran conjugates were generated in mice,[184] no reports of antibodies against 
dextran conjugates in humans have been published to date.[160] 
Offering certain space for modifications at numerous positions, dextran has come into the focus as viable carrier 
for diverse compounds.[160, 175] Historically, oxidation of glucose hydroxyls was chosen to generate reactive 
aldehydes that were subsequently addressed by a suitable nucleophile, e.g. primary amine (Figure 16). Thus, 
periodate-oxidized dextran bearing numerous aldehyde moieties was reacted with a primary amine resulting in 
a Schiff base. Subsequent reduction yielded stable protein- or drug-dextran conjugates. In general, periodate 
oxidation is a standard procedure towards linkage of polysaccharides and diverse biomacromolecules.[160, 175] For 
instance, soy trypsin inhibitor-[185] and uricase-dextran[186] conjugates were generated as well as a somatostatin-
dextran conjugate with low-nanomolar binding affinity, extended PK profile and prolonged half-life in mice.[187] 
A superoxide dismutase- (SOD)-dextran conjugate retained over 80 % activity when conjugated in average with 
4.4 dextran units per SOD, while the anti-inflammatory activity of SOD was doubled.[188] Additionally, the enzyme 
was found to be more resistant to H2O2-mediated inactivation and revealed a prolonged half life.[188] The 
prolonged half-life was conditioned by an enlarged hydrodynamic radius combined with the increased stability 
of the protein-dextran conjugates.[188] In additional studies, reduced immunogenicity of antibodies or Fabs 
bound to dextran scaffolds was revealed.[189, 190] However, the presence of numerous amine moieties on most 
proteins led to rather heterogenous dextran-protein conjugates and crosslinking of the proteins.[160] 
Other historical conjugation methods made use of phosgene activation or cyanogen halides.[160] However, the 
application of these methods has declined over the years. Moreover, carboxymethylation or the application of 
carbonyl diimidazole (CDI) as activating agent were used to address dextran’s hydroxy groups.[191, 192] The former 
methodology generates carboxymethyl dextran by utilizing bromoacetic acid under basic conditions, whereas 
the latter is applied to synthesize dextran equipped with multiple amine groups.[191, 192]. In a recent report, 
Richter et al. applied dextran for the covalent attachment of multiple BH3 peptides to effectively induce 
apoptosis by addressing the intracellular target Bcl-xl in a multivalent manner.[193] In this approach uptake was 
achieved by nucleofection or by application of cell penetrating peptides (CPPs), that were covalently attached 
to the dextran backbone. To this end, carboxyethylation was performed by a Michael-type addition of 
acrylamide under basic conditions followed by hydrolysis of the generated amide. Interestingly, 
carboxyethylation was observed solitarily at the position C2, as shown by 2D-NMR analysis of the resulting 
constructs. Subsequently, a thiol-bearing amine linker was incorporated at the dextran backbone upon 
formation of an amide bond. Conjugation of thiol-bearing Bid-BH3 gave rise to potent apoptosis-inducing 
constructs. Multivalent binding of Bid-BH3 peptides conjugated to dextran scaffold led to the replacement of 
Bac-protein, which triggers the formation of membrane pores by oligomerization.[193] In this approach either 
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nucleofection of the multivalent polysaccharide-peptide constructs or the application of CPPs conjugated to the 
scaffold both resulted in effective triggering of apoptosis.[193]  
The reducing end of dextran comprises one distinct aldehyde moiety due to equilibrium between the 
closed-chain (cyclic) and open-chain (acyclic) glucose forms (Figure 15). This solitary moiety opens space for 
modification with a primary amine by reductive amination, lactonization or oxime ligation. Thus, numerous 
approaches were reported to conjugate small molecules,[174] enzymes[194] or polymers[195, 196] to the reducing end 
of dextran. For instance, Valdivia et al. combined reductive amination of a diamine with mTG-catalyzed 
conjugation of the resulting amine-bearing dextran to catalase.[197] This approach yielded a more stable 
protein-dextran conjugate with increased catalase activity and improved pharmacokinetic properties as an 
increased plasma half-life and reduced total clearance in rats was observed.  
Since the early 1980s dextran has been applied as a multivalent scaffold for the generation of ADCs.[198-203] In 
these hybrid architectures, dextran was applied as a bridge between an antibody and cytotoxic payloads. 
Hurwitz et al. conjugated daunomycin and cytosine arabinoside to aldehydes of periodate-oxidized dextrans.[198] 
After the drugs had been attached, the antibody was bound to the remaining aldehydes via its lysines.[198] 
Consequently, the formed conjugates were stabilized by partial reduction either by sodium borohydride or 
sodium cyanoborohydride. In addition, adriamycin was conjugated by formation of a stable hydrazone between 
hydrazide groups located on dextran scaffolds and the keto group of the tetracycline side-chain. The antibodies 
were subsequently linked to this derivative via glutaraldehyde.  
 
 
Figure 16. Periodate oxidation of dextran resulting in aldehyde moieties and a corrupted glycoside backbone. Modified from Maia et al.[204] 
 
Periodate-oxidized 5-fluorouridine was coupled to dextran in a similar fashion. Both approaches applied sodium 
cyanoborohydride to stabilize the generated compounds. The dextran-bridged ADCs maintained high drug 
activity and only a 50 % loss of antibody activity was observed. Furthermore, two approaches applying the 
above-mentioned procedure were used to couple daunomycin to monoclonal mouse or polyclonal horse 
antibodies targeting rat α-fetoprotein (AFP).[201, 203] In another approach, Shih et al. conjugated methotrexate 
(MTX), to a monoclonal anti-carcinoembryonic antigen (CEA) antibody using an aminodextran carrier system.[200] 
To that end, dextran was partially oxidized and the resulting polyaldehyde was reacted with 
1,3-diamino-2-hydroxypropane yielding an amino-dextran after a reduction with sodium borohydride. MTX 
conjugation was attained by either utilizing N-hydroxysuccinimide(NHS)-activated MTX or by conjugation under 
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EDC activation. The MTX-dextran conjugate was linked to an oxidized IgG obtained by sodium periodate 
oxidation followed by a stabilizing reduction step. The generated DAR 30-50 molecules showed a significant 
retention of binding capacity and possessed improved pharmacokinetic properties in BALB/c mice and in 
hamsters. Further, these compounds demonstrated cytotoxicity against HT-29 or LoVo colon tumor cells in vitro. 
However, a lower cytotoxicity of dextran-bridged MTX-ADCs, compared to the solitary toxin, was found on LoVo 
cells. The authors attribute this observation to a different receptor-mediated uptake mechanism of the 
antibody-dextran conjugate which is dependent on efficacy of antibody internalization and receptor density. It 
should be noted that the extra amino groups on the dextran may confer the conjugate to non-target cells and 
may provoke aggregation with negatively charged antigens.[200] Furthermore, Oseroff et al. applied dextran to 
conjugate multiple chlorin e6 photosensitizer payloads to a monoclonal antibody.[199] Periodate-oxidized dextran 
was conjugated with ethylenediamine and with amine-modified chlorin e6 monoethylenediamine monoamide 
derivative to generate partially amine-modified dextran equipped with multiple photosensitizers. Subsequently 
conjugation to oxidized anti-T cell mAb anti-Leu-1 resulted in ADCs that exhibited DARs up to 36. The generated 
conjugates retained most of their binding activity, while the quantum efficiency of the bound chlorin e6 was not 
affected. Further, these ADCs revealed a light- and target-dependent photodestruction on HPB-ALL T-cell 
leukemia cells in vitro.[199] In general, being applied as cargoes in ADCs, photosensitizers can improve the 
performance of antibodies which possess certain off-target binding, as laser irradiation is needed to trigger their 
cytotoxicity, thus specifying and directing an application site. 
However, all the above-mentioned ADCs were conjugated stoichiometrically by addressing either the antibody’s 
lysines or the stoichiometrically generated aldehydes of an oxidized antibody, resulting in heterogenic ADCs. 
Furthermore, payload was conjugated to oxidized-dextran, which additionally results in heterogeneity of the 
corrupted polysaccharide.  
 
1.7. Multivalent Binding and Death Receptor 5 Clustering 
 
Multivalency is often used by nature to achieve strong interaction between different interfaces or molecules by 
magnification of the multiple weak forces (Figure 17).[205] Arctium, also known as burdock, is a prominent 
example of this effect. Its, seeds composed of thousands of miniature hooks and loops, can easily cling to and 
hold on fur of animals or clothes, though a single hook cannot.[206] Velcro-type releasable fasteners are an 
example of bioinspired applications proposed by the swiss engineer George de Mestrals after observing sticking 
burdock seeds.[207] Another example obtained from nature is the wing-locking device of beetles, which utilizes 
densely populated microtrichia on the cuticular surface to interlock their wings to maximize lateral adhesion 
and prevent lateral movement.[206, 208] 
In the immune system the first-line defense also takes advantage of multivalent binding. For instance, IgM that 
represents the first immunoglobulin produced after exposure to an antigen is secreted either in a pentameric 
form connected by a joining chain or as a hexamer lacking the joining chain comprising ten or twelve antigen-
binding sites, respectively.[209] IgM antibodies exhibit rather weak binding affinities compared to 
affinity-maturated IgGs. However, the multivalent binding of this immunoglobulin mediates an avidity-enhanced 
functional binding capacity. Notably, not all ten, respectively twelve, antigen-binding sites can bind 
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simultaneously due to steric hindrance. Furthermore, IgA representing the major class of antibodies present in 
mucosal secretions and being part of first-line defence against inhaled and ingested antigens is produced in a 
dimeric form.[210] Being synthesized locally at mucosal sites, it is transported across the epithelial cell boundary 
and out to secretion by interaction with the polymeric immunoglobulin receptor.[210] These dimers are linked by 
an end-to-end connection of the heavy chains, and stabilized by disulfide bridges and a joining chain (Figure 
3).[210] Additionally, IgA has been found in serum of many species acting as second-line defense against 
pathogens which have breached the mucosal surface.[210] In general, immunoglobulins possess at least two 
binding sites, thus demonstrating that multivalency is a useful tool to enhance binding. 
 
 
Figure 17. A multiple ligand-bearing scaffold enables multivalent binding to a cell surface. 
 
In recent years, besides the classical chemotherapy or targeted approaches, killing of tumor cells by activation 
of apoptosis-triggering cascades has become a promising field for investigations.[211] Herein, a major 
breakthrough was the discovery of the tumor necrosis factor (TNF) superfamily and TNF-related apoptosis-
inducing ligand (TRAIL).[211] TRAIL is a type 2 transmembrane protein naturally present as a trimer on the surface 
of activated immune cells (e.g. natural killer cells and CD8+ T cells).[211] The fact that TRAIL is capable of inducing 
programmed cell death of a wide range of cancer cells while leaving healthy cells untouched, made it a promising 
anticancer agent.[212, 213] Among the five known receptors of TRAIL, i.e. death receptor 4 (DR4), death receptor 5 
(DR5), TNF-related apoptosis-inducing ligand receptor 3 (DcR1), TNF-related apoptosis-inducing ligand receptor 
4 (DcR2), and osteoprotegerin (OPG), only DR4 and DR5 possess a functional ~90 amino acids stretch called death 
domain (DD) which is a prerequisite for efficient signaling leading to apoptosis.[211] Notably, OPG harbours a 
complete DD, but as it is expressed as soluble receptor, it is not able to trigger apoptosis.[211] Furthermore, DcR2 
possesses an intracellular domain but only a truncated DD.[211] Binding of timeric TRAIL leads to the 
oligomerization/aggregation of bound receptors, which is the first critical step for programmed cell death upon 
formation of the so-called death-inducing signaling complex (DISC) (Figure 18).[211] Subsequently, this binding 
allows for the recruitment of adapter Fas-associated protein with death domain (FADD) also possessing a DD, 
which constitutes the DISC. Further, recruitment of pro-caspase-8 and/or -10 and its interaction within the DISC 
complex allows for their activation and release in the cytosol resulting in apoptosis mediated by cleaving of 
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effector caspase-3 and/or-7.[213] An additional backup pathway proceeding via mitochondria is initiated by the 
cleavage of Bid. Subsequently, truncated Bid (tBid) translocates to mitochondria to induce the activation of Bax 
and/or Bak resulting in the release of cytochrome c, which triggers apoptosis by the activation of caspase-9.[213]  
 
 
 
Figure 18. Proposed mechanism for apoptosis triggering upon DR5 receptor-clustering.modified from Dubuisson et al.[211] 
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DR4 and DR5 are often co-expressed on the same cell. However, DR5 seems to be more important for induction 
of apoptosis.[214] It is proposed that DR5 forms large clusters (~300-500 nm) within the membrane upon ligand 
binding, which are not the co-localizations in cholesterol-rich membrane domains as was believed for a long 
time.[215] Further, highly structured networks held together by receptor dimers were found, underlining that the 
formed clusters are not random aggregates of the receptors[215] However, the relationship of trans-membrane 
helix dimerization, receptor activity and membrane cholesterol is still too complex to be fully understood.[215] 
Therefore, it is not clear if the membrane itself plays an active role in these processes.[215] 
Due to their ability to trigger apoptosis, DR4 and DR5 became promising targets for tumor treatment. However, 
in clinical trails both soluble TRAIL and agonist antibodies targeting either DR4 or DR5 failed to demonstrate the 
desired efficacy.[213] Indeed, dulanermin developed by Genentech, a recombinant protein that encodes TRAIL 
from amino acid 114-281, did not show sufficient therapeutic activity.[216, 217] Additionally, TRAIL was found to 
suffer from resistance induced by decoy receptors and is likely to promote cell migration and metastasis.[218, 219] 
Furthermore, TRAIL-targeting antibodies, like mapatumumab[220] that combines selectivity with effector 
functions of the Fc of an antibody, were developed. However, though being well-tolerated, they often lack 
efficacy due to their bivalent architecture compared to trivalent natural TRAIL.[211] Novel TRAIL versions aimed 
at improved stability and half-life, relied on genetic fusion towards TRAIL single-chain trimers. The same genetic 
approach is used to fuse it with single-chain variable fragments (scFvs) and Fc fragments. In addition, conjugation 
with chemical drugs or nanoparticles and expression on the cell surface of delivery cells have been reported.[211] 
For instance, circularly permuted TRAIL (CPT),[221, 222] a recombinant mutant of human TRAIL introduced by 
Beijing Sunbio Biotech Co. Ltd., represents the best and most promising TRAIL derivative so far.[211] CPT exhibited 
better stability, half-life, and stronger antitumor activity compared to dulanermin and was found well-tolerated 
in early phase II clinical studies.[211, 221, 222] However, CPT is, like parent TRAIL, supposed to suffer from decoy 
receptors and is believed to promote migration and metastasis.[211]  
Considering the drawbacks of the mentioned compounds, researchers around the globe investigated novel 
TRAIL-inspired approaches that rely on multivalent derivatives of antibodies or peptidic binders, among them 
multimerization of small binding mimetics of antibodies, e.g. scFvs[223] or single-domain antibodies from sharks 
or camelids[224] (VNAR or VHH). Further, oligovalent binders based on IgM, frameworks relying on either 
adamantane[225, 226] or C4b-binding protein (C4BP)[227] have been currently reported. Interestingly, TAS266, a 
tetrameric nanobody linked by three 35 amino acid peptides each representing one of these highly potent 
binders, was found hepatotoxic, which may be attributed to its high potency, immunogenicity, and possibly 
increased DR5 expression on hepatocytes.[224]  
The peptide-based approaches rely on the death receptor 5 targeting peptide (DR5TP)[228] that solitarily was not 
capable of inducing apoptosis. However, upon multimerization on the mentioned scaffolds effective 
programmed cell-death was observed. Notably, the authors depicted a certain spatial orientation of the ligands 
as indispensable element for efficacy.[225, 227] A review giving a deeper insight into the current status of DR4 and 
DR5 targeting antibodies and derivatives can be found elsewhere.[211] 
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2. Objective 
 
This doctoral research was focused on application of dextran polysaccharide to tailor-made next-generation 
antibody-drug conjugates and other hybrid architectures. To that end, addressing several crucial issues for ADCs 
regarding their water solubility and multivalent applications should expand the scope of these biomolecules. In 
particular, the ultimate goal of this work was the development of a highly hydrophilic, modular and multivalent 
scaffold based on dextran polymer, that allows not only for multivalent presentation of desired payloads in a 
controlled fashion, but site-specific, orthogonal conjugation with a biomolecule of choice. 
 
The first part of this thesis was aimed at the generation of potent antibody-drug conjugates (ADCs) comprising 
a high drug-to-antibody ratio (DAR) and retaining a preferred hydrophilic profile. ADCs are multicomponent 
biomolecules that combine the targeting properties of an immunoglobulin with the cytotoxic potency of a 
covalently attached cargo. Since only a limited number of the administered ADCs is able to reach their cellular 
target, the cytotoxic payload they carry needs to be highly potent. That can be achieved by improving its potency 
or applying higher numbers of copies, thus making use of a multivalent organization. However, considering the 
fact that the majority of commonly used toxins are strongly hydrophobic compounds, highly loaded ADCs often 
suffer from poor solubility and unexpected aggregation, which can become crucial regarding pharmacokinetics, 
immunogenicity, and efficacy. Therefore, these architectures require careful design in terms of conjugation site 
and number of attached payloads. Indeed, the average DAR of most ADCs does not exceed 3-4, and generation 
of high-DAR hydrophilic ADCs is an important and challenging task.  
In the present work, this issue should be addressed by introducing a hydrophilic, modular scaffold enabling 
equipment of an antibody of choice with a potent cytotoxin in a desired number of copies. To that end, dextran 
should be used. It is an FDA-approved biocompatible polymer reported to enhance half-life, improve the thermal 
stability and pharmacokinetics, and reduce immunogenicity of conjugated proteins. Due to its structure 
comprising repeated sugar units, dextran bears multiply addressable functional groups. It should be investigated 
as modular hydrophilic carrier system. To that end, a viable synthetic approach to novel dextran-ADC constructs 
should be established providing a possibility for the tailoring of toxin loading. Subsequently, the question should 
be answered, if and how the polarity of a dextran scaffold is influenced upon loading with cargoes and 
conjugation to an antibody. For that purpose, dextran polysaccharide should be ligated with a commonly applied 
antibody site-specifically and subsequently equipped with multiple units of a highly potent hydrophobic payload. 
The resulting high-DAR ADC should be validated regarding its hydrophilic properties, binding capacity of the 
parental antibody and toxicity of a payload in vitro. 
 
In the second part of this doctoral study, the modularity of the novel multimerization scaffold should be 
validated by attaching multiple peptidic ligands. Death receptor 5-targeting peptide (DR5TP) should be applied 
as ligand for this proof-of-concept study. These ligands are known to trigger apoptosis of malignant tumor cells 
in the case when they adopt a special orientation. Hence, it should be investigated if the dextran backbone is 
suitable to provide enough variability to effectively bind and finally cluster death receptor 5 (DR5) which is 
known to trigger apoptosis when bound in a multivalent manner by tumor necrosis factor related apoptosis 
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ligand (TRAIL). This concept should overcome the need of spatial orientation as prerequisite for efficient 
multivalent receptor clustering that was previously reported. To that end, DR5TP should be attached to dextran 
backbone in multiple copies. On that account, the potential to trigger apoptosis should be visualized by cell 
proliferation assays on DR5-overexpressing cells in vitro. Furthermore, it should be elucidated if site-selective 
enzymatic conjugation to a protein of choice affects binding and/or potency of the generated hybrid 
compounds. Thus, dextran scaffold should be site-specifically conjugated to a fraction crystallizable (Fc) 
fragment of an antibody that is solitary not to able to target DR5-positive cells and the potency should be 
assessed in respective biologic assays in vitro 
 
Furthermore, an additional approach which substantiates the modularity of dextran as multivalent scaffold for 
payloads of diverse nature was performed. To that point dextran should be examined as a vehicle for multiple 
attachment of metal-chelating agents able to carry ions valuable for radio-imaging or -therapy. Therefore, 
dextran should be decorated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) which is a 
widely applied metal chelator. Furthermore, it should be validated if DOTA-loaded dextran is able to complex a 
non-radioactive metal as test substance. Furthermore, the biodistribution of DOTA-dextran compound should 
be investigated in a preliminary in vivo study. This study should answer the question if dextran represents a 
promising carrier for radio-imaging and -therapy. 
 
The third part of the thesis should delineate a detailed overview of ADC assembly applying microbial 
transglutaminase (mTG), as to date, notwithstanding numerous reviews of the field, a comprehensive view of 
application of transglutaminase for generation of therapeutics is missing. Thus, it intends to give a comparative 
survey that describes conjugation sites, motifs and procedures, as well as cellular targets, and applied linkers 
and toxins. Furthermore, this review should provide a thorough overview of research groups and companies 
working on ADCs assembled under mTG catalysis.  
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5. Additional Results 
 
To further test the modularity of dextran, we examined it as a carrier for multiple metal chelators. This concept 
may open space for attachment of a higher number of radioisotopes per targeting protein and improving 
pharmacokinetic properties of small targeting proteins like affibodies. For that purpose, we applied 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), a well-known chelator for various metal ions. Dextran 
was equipped with a Boc-protected amine at the reducing end followed by carboxyethylation at the C-2 of the 
glucose repeating units. Subsequent, conjugation of an azide-bearing amine linker and deprotection of the 
reducing end to generate a free amine moiety was performed (Figure 19). Dextran was equipped with 4.2 or 7.5 
azide moieties which could be easily visualized by NMR analysis as previously described (see cumulative section 
1 and 2, Figure 20) 
 
Figure 19. Synthesis scheme for dextran bearing multiple azide moieties on the glucose repeating units and a Boc-protected 
cadaverine at the reducing end. 
 
Subsequent conjugation with BCN-DOTA purchased from Chematech (Dijon, France) followed by purification 
applying size-exclusion chromatography led to dextran bearing multiple DOTA (Figure 21). Hereby, SPAAC was 
performed as reported in the cumulative section regarding dextramabs. Briefly, dextran bearing multiple azide 
groups was dissolved in 1 × PBS and 2.5 eq of BCN-DOTA per azide moiety was added and the reaction mixture 
was shaken at 30 °C for 3 h. Pure product was isolated by PD-10 desalting columns and SEC on a BioSep-
SEC-s2000, 300 x 7080 mm, 5µM (Phenomenex) applying an isocratic procedure (40 min, water).  
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Figure 20. NMR spectra of azido-dextran cadaverine. (top) Dextran equipped with 4.2 azide moieties per dextran and dextran 
equipped with 7.5 azide moieties(bottom). 
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Figure 21. Scheme of dextran quipped with multiple DOTA 
 
The number of conjugated DOTA groups per dextran was assessed by the complexation of Cu2+ ions, which 
results in measurable absorption at 265 nm. In a first step a calibration curve for the Cu2+-complex of DOTA was 
generated to get access to the molar extinction coefficient of the formed complex. Therefore, a serial dilution 
bearing BCN-DOTA at different concentrations (0.01-0.2 mM) and CuSO4 (500 mM) was prepared. Photometric 
analysis revealed the molar extinction coefficient (4147 L·-1·cm) that was obtained by linear regression applying 
Beer–Lambert law. Subsequent, measurement of complexation of Cu2+ by DOTA-dextran-cadaverine constructs 
in three different concentrations indicated that in average 3.2 or 5.3 Cu2+-ions were complexed by DOTA-dextran 
conjugates, respectively. These measurements were performed in triplicates. To test the biodistribution of the 
assembled DOTA-dextran conjugates in vivo studies in mice are currently ongoing. In a prospective proof-of 
concept-study, DOTA-dextran conjugates should be linked to commonly applied targeting proteins e.g. 
affibodies, that suffer from poor solubility, aggregation and precipitation due to their intrinsic hydrophobic 
properties. 
  
 Danksagung   128 
6. Danksagung 
 
In diesem Teil möchte ich mich herzlich bei allen Menschen bedanken, die mich während der Zeit meiner 
Promotion und während der Niederschrift dieser Arbeit begleitet haben! 
 
Mein aufrichtiger Dank gilt den folgenden Personen: 
 
In erster Linie gilt dieser Dank meinem Doktorvater Prof. Dr. Harald Kolmar, der mir nicht nur die Möglichkeit 
gegeben hat, diese Arbeit anzufertigen, sondern mir auch stets ein erreichbarer Ansprechpartner war und mit 
Rat und Tat zur Seite gestanden hat. Sein unermüdliches Streben nach neuen Synthesen und Projekten hat 
meine Arbeit vorangetrieben und mir dennoch den Freiraum gelassen, meine eigenen Ideen zu entwickeln, zu 
diskutieren und diese auch umzusetzen. Die Zeit in deiner Arbeitsgruppe, sei es im Labor oder im Kleinwalsertal, 
war einfach spitze - Danke für diese Zeit, Harald! 
 
Prof. Dr. Katja Schmitz, Prof. Dr. Markus Biesalski und PD Dr. Meckel danke ich für die Übernahme des 
Korreferats bzw. für ihre Arbeit als zweiter Fachprüfer. 
 
Meinen Co-Autoren Lukas Deweid, Thomas Pirzer, Desislava Yanakieva, Simon Englert, Bastian Becker, Arturo 
Maccarón, Sebastian Bitsch, Dr. Olga Avrutina gilt mein Dank für die gute Zusammenarbeit in unseren 
Projekten. Insbesondere danke ich Lukas Deweid, der es geschafft hat, sich auf alle meine Publikationen zu 
schleichen. 
 
Dr. Olga Avrutina danke ich für das Lektorat meiner verfassten Texte. Du hast mir wirklich geholfen und mir 
beigebracht, wie man meinen Labortätigkeiten auch einen würdigen schriftlichen Rahmen gibt. 
 
Simon „Schirmon“ Englert und Ata „A-TAU“ Ali gilt mein Dank als meine steten Begleiter, ob zu früher Stunde 
im Fitnessstudio, Biergarten, Skiurlaub, Billiardschuppen, in der Krone oder auf der besten Hüttentour aller 
Zeiten. Auf euch kann ich immer zählen. Die Zeit mit euch wird mir stets in Erinnerung bleiben!  
 
Bastian „Spritzel“ Becker danke ich für die unermüdliche Hilfe und das Ertragen meiner Fragen zu Synthesen 
und Berechnungen. Ohne dich als meinen längsten Weggefährten, die unendlichen Tassen an Kaffee, sei es in 
der Kuhle oder in der Stadtmitte und die gemeinsame Zeit des aktiven Betreuens der Praktikanten wäre es nicht 
dasselbe gewesen. 
 
Dr. Julius „Jules“ Grzeschik für unsere gemeinsamen Abende auf der unvergessenen Dachterrasse, im Kessel 
und im Stadion, ob in Darmstadt, Frankfurt oder Hannover. Dank dir habe ich meinen Kaffeekonsum 
verdreifacht. Danke auch für deine umfassende Hilfe, als sich schließlich das Ende der Zeit anbahnte und alles 
zu Papier gebracht werden musste. 
 Danksagung   129 
Steffen „Ehh-Steffen“ Hinz für seine bis ins kleinste Detail ausgearbeiteten Planungen der gemeinsamen 
Urlaube und das Teilen seines tiefgründigen Wissens über die heimischen Vogelarten. Danke für die 
Beantwortung meiner biologischen Fragen, auch dank dir kann ich heute einige „Biologenpunkte“ mein Eigen 
nennen. 
 
Dr. Doreen ”Dorn” Könning und Dr. Andreas Christmann gilt mein besonderer Dank dafür, dass sie stets für 
mich einstanden, wenn es nötig war. Doreen, ohne dich ist das Mittagessen in der Mensa und der sonntägliche 
Goldrausch nicht dasselbe. 
 
Arturo „Arturito“ Macarrón für seine positive und spanische Art, die mir jeden Tag Lust auf Fiesta macht. Danke 
für die schönen Abende bei dir, ob am Lagerfeuer, beim Kickern oder beim Dart-spielen. 
 
Adrian „Adi“ Elter gilt mein Dank für seine belustigenden Versuche, seine „allerbeste“ Beziehung zu einer 
Kollegin zu verheimlichen und seine großzügige Art als Gastgeber bei jedwedem Anlass. 
 
Desislava Yanakieva und Thomas Pirzer gilt mein Dank für die Vorbereitung unzähliger Platten für Toxassays, 
Zellen fürs FACS und generell für die Einführung in die Arbeit mit Zellen. Dank euch kann jetzt auch ein Chemiker 
ein wenig in der Zellkultur arbeiten. 
 
Der gesamten Pizza-Pommes-Crew bestehend aus Simon Englert, Ata Ali, Steffen C. Hinz, Janna Sturm, Dominic 
„X-Men“ Happel und Jan Bogen für die unzähligen Abfahrten und die super Zeit im Zillertal. Ich werde nie 
vergessen, wie wir nach dem einen Abend am nächsten Tag auf den Skiern gestanden haben. 
 
Dr. Thomas Pirzer, Bastian Becker, Lukas Deweid, Arturo Macarrón, Ata Ali, Jan Habermann, Sebastian Bitsch 
und allen anderen aus der Tischkicker-Crew danke ich für jedes einzelne Spiel, ohne die einem manchmal der 
Kopf für die Arbeit nicht frei genug gewesen wäre. Es war und wird mir eine Freude sein, euch in weiteren 
Matches entgegenzustehen. Arturito, es war mir eine Ehre dich krabbeln zu sehen. 
 
Barbara Diestelmann für die Unterstützung bei jeder organisatorischen Frage und allen weiteren Wehwehchen 
im Laufe meiner Promotion. Du hältst den Laden hier zusammen! 
 
An Cecilia “Cilli” Gorus ohne die das Labor kaum existieren würde und für jedes „Guten Morgen Hendrik“. 
 
Dr. Stefan Zielonka, Dr. Heiko Fittler, Dr. Julius Grzeschik und Dr. Stephan Dickgiesser gilt mein besonderer 
Dank für die wunderschöne musikalische Untermalung meiner Anfangszeit. Emil Schlemihl, Madchild und Wing 
werden mich mein ganzes Leben begleiten. Stephan dir gilt mein Dank insbesondere, denn ohne dich hätte ich 
den Dieter niemals erlebt! 
 Danksagung   130 
Adrian Elter, Dr. David Fiebig, Lara Neureiter, Dana Schmidt, Anja Hofmann, Valentina Hilberg, Jan Bogen, 
Janine Becker, Dr. Vanessa Siegmund, Dr. Daichi Nasu, Sascha Knauer, Dr. Christina Uth und allen weiteren 
aktuellen und ehemaligen Mitarbeitern des AK Kolmar für jedwede Unterstützung, ob im Labor oder von 
organisatorischer Seite. Die Zeit, ob im Labor, auf Radtouren, im Biergarten, in der Mensa, beim Dieter, bei 
Alexander Markus oder im KWT, war unvergesslich. Vielen Dank für die schöne Zeit! 
 
Ein riesiges Dankeschön gilt meiner Familie und meinen Freunden, die mich zeitlebens unterstützt, gefördert 
und so genommen haben, wie ich bin. Insbesondere gilt dieser Dank meinen Eltern Jeanette und Günter, meiner 
Schwester Kirstin sowie meinen Großeltern Erika, Werner und Martha. Danke für die Unterstützung, den 
Rückhalt, Zuspruch und euren steten Glauben an mich. Ohne euch wäre ich nicht der Mensch, der ich heute bin! 
 
Mein wichtigster Dank gilt meiner Freundin Julia Ebert für jeden gemeinsamen Tag, während dieser Promotion. 
Danke, dass du mich immer unterstützt, mir beistehst und meiner, nicht immer einfachen, Art mit einem Lächeln 
entgegenstehst. Dein Glaube an mich in schwierigen Phasen und deine Unterstützung, haben mich immer 
wieder vorangetrieben und mir wieder Zuversicht geschenkt. Ohne dich wäre ich manchmal verzweifelt. Danke, 
für jeden einzelnen Moment!  
 Affirmations   131 
7. Affirmations 
 
Hendrik Peter Günter         Darmstadt, 6.12.2019 
Gutenbergstraße 45 
64289 Darmstadt 
Schneider@Biochemie-TUD.de 
017647361038 
 
 
 
 
 
 
Erklärung 
Ich erkläre hiermit, dass ich meine Dissertation selbstständig und nur mit den angegebenen 
Hilfsmitteln angefertigt habe. 
 
 
 
 
 
_______________________________ 
Hendrik Peter Günter Schneider 
 Affirmations   132 
Hendrik Peter Günter         Darmstadt, 6.12.2019 
Gutenbergstraße 45 
64289 Darmstadt 
Schneider@Biochemie-TUD.de 
017647361038 
 
 
 
 
 
 
Erklärung 
Ich erkläre hiermit, noch keinen Promotionsversuch unternommen zu haben. 
 
 
 
 
 
_______________________________ 
Hendrik Peter Günter Schneider 
  
 Affirmations   133 
Hendrik Peter Günter         Darmstadt, 6.12.2019 
Gutenbergstraße 45 
64289 Darmstadt 
Schneider@Biochemie-TUD.de 
017647361038 
 
 
 
 
 
 
Erklärung 
Ich erkläre hiermit, dass die elektronische Version der Doktorarbeit mit der schriftlichen Version 
übereinstimmt. Die elektronische Version liegt dem Prüfungssekretariat vor. 
 
 
 
 
 
_______________________________ 
Hendrik Peter Günter Schneider 
 
